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Telomeres, the nucleo-protein complexes at the ends of linear chromosomes, 
have critical roles in genome stability, cancer, and aging. Early work by B. 
McClintock and H.J. Muller demonstrated that eukaryotic chromosome ends contain 
specialized structures that prevent recognition and processing by the DNA repair 
machinery. The importance of these structures is illustrated by studies showing that 
loss of chromosome end protection results in massive genome instability and cell 
death. Although Muller and McClintock’s initial observations were made several 
decades ago, little progress has been made in understanding the molecular markers 
that distinguish naturally occurring chromosome ends from de novo DNA double 
strand breaks, especially in humans. Using a novel system to specifically target 
proteins of interest to human telomeres, we have uncovered a role for hRAP1 in 
protecting telomeres from non-homologous end joining (NHEJ). We find that 
telomeric DNA containing hRAP1, but not TRF2, is protected from NHEJ in vitro. 
Furthermore, we show that telomeres containing TRF2 but not hRAP1 can be fused 
by NHEJ in vivo, and we also demonstrate that targeting hRAP1 to telomeres in vivo, 
even when TRF2 is not detected, is sufficient to protect telomeres from NHEJ. These 
results identify hRAP1 as a critical mediator of telomere protection and genome 
stability in humans. Related to this work, we have also identified a new type of 
telomere dysfunction associated with semi-conservative replication stress at human 
telomeres. This new type of telomere dysfunction is telomerase and NHEJ-
independent and may require the RecQ helicase WRN for its formation, suggesting 
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that it is related to telomere entanglements observed upon induction of replication 
stress in fission yeast. The finding that this type of dysfunction is conserved from 
yeast to man is a testament to the underappreciated role of semi-conservative DNA 
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Introduction to Telomeres and Significance of Research 
 
I.1: The Eukaryotic Genome 
 All organisms are comprised of cells, which are considered to be the 
fundamental unit of life on Earth. The first description of cells is from the 17th 
century polymath Robert Hooke. While inspecting cork bark at high magnification 
using the newly invented microscope, Hooke famously noted the similarity in shape 
between mysterious structures in cork bark and the cells in which cloistered monks 
reside [1]. Since their initial description three hundred years ago, much has been 
learned about cells including their mechanisms for survival, propagation, and 
communication. To date, though, the most important discovery about cells was the 
realization that they represent the fundamental unit of life on Earth. 
 A prerequisite for being the basic unit of life is the ability to faithfully 
transmit information from the parental cell to its progeny. To facilitate faithful 
transmission of information, cells store information in the form of highly stable 
deoxyribonucleic acid (DNA) polymers. In eukaryotes, these polymers are tightly 
spooled around histones, creating protein:DNA complexes termed nucleosomes. 
Nucleosomes are then further packaged into structures called chromosomes, and the 
collection of chromosomes within the cell is referred to as the genome (Figure 1.1). 
Cells have numerous mechanisms to safeguard information contained within the 
genome, including mechanisms to prevent and repair damage to DNA, and a 
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complex machinery to ensure that each daughter cell receives and maintains the 
appropriate numbers and types of chromosomes. 
 Chromosomes can be maintained in two states, circular and linear.  Though 
most bacteria and archaea have circular chromosomes, naturally occurring 
eukaryotes invariably rely upon linear chromosomes for genome maintenance[2].  
Each of these types of chromosomes has its own benefits and limitations. For 
example, circular chromosomes are easy to replicate and segregate, but their 
maximum size is quite small. On the other hand, linear chromosomes are inherently 
difficult to fully replicate and segregate, but can handle much larger amounts of 
DNA[3]. To accommodate their complexity, eukaryotes are forced to rely upon 








Figure 1.1. Schematic of the compaction and storage of DNA within the eukaryotic 
cell. Uncopyrighted image reprinted from National Human Genome Research 
Institute. 
 
 Linear chromosomes pose multiple challenges for the organisms that contain 
them. Each of these problems has been met with a plethora of creative and efficient 
solutions that demonstrate both the difficulty in maintaining linear chromosomes and 
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the power of evolution to cope with them. Without the ability to circumvent the 
inherent difficulties of carrying linear chromosomes, genome complexity would be 
substantially constrained and the eukaryotic cell in its current form would not exist. 
Thus, a discussion of the fundamental mechanisms that promote genome stability in 
eukaryotes, as well as a description of the problems associated with maintenance of 
linear chromosomes are necessary before further exploration of this topic.  
  
I.2: Distinguishing chromosome ends from DNA breaks 
Cells encounter a diverse array of mutagenic insults including UV light, 
genotoxic chemicals, radiation, and reactive oxygen species. Each of these insults 
can damage DNA, potentially leading to deleterious changes in DNA sequence that 
may ultimately impact RNA and protein sequences, structures, and functions. To 
avoid accumulation of potentially deleterious mutations, cells have numerous 
mechanisms for both preventing DNA damage and for repairing damage once it has 
occurred. 
 
I.2a Why are DNA damage and double strand breaks so harmful? 
  One type of damage that is particularly harmful to cells is the DNA double 
strand break (DSB). DSBs occur when phosphodiester bonds on complementary 
strands are broken. DSBs can be disastrous to the cell for several reasons. First, a 
DSB removes the connection between the centromere and at least one region of a 
chromosome. Because centromeres provide the physical link between DNA and the 
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chromosome segregation machinery, the estrangement of one region of a 
chromosome from its centromere would result in daughter cells not receiving their 
full complement of genetic material. If an essential gene was present on a 
chromosome fragment that was not properly allocated to the daughter cell, then the 
daughter would not be viable. Another problem associated with DSBs is that 
transcription of mRNA from DNA can not occur across a broken phosphodiester 
bond. The inability to properly transcribe genes can have disastrous results for the 
cell, including sterility and death.  Due to the potential lethality of unrepaired DSBs, 
cells actively and effectively resist harboring such insults. 
 
I.2b: Sensing a DSB 
Since DSBs can be deleterious to cells, every cell, from the simplest bacteria 
to syncytial invertebrate gonads, contains a mechanism for quickly sensing and 
repairing de novo DSBs. In eukaryotes, when two phosphodiester bonds are broken 
on opposing DNA strands, changes in the local chromatin environment occur[4]. 
During this process, Ser139 on histone H2A (called γ-H2AX) at the site of the DNA 
break is phosphorylated by DNA damage sensing kinases, including the PI3K-related 
kinases ataxia-telangietscia mutated (ATM) and ATM-related kinase (ATR) 
(reviewed in [5]). This phosphorylation can extend to neighboring histones several 
hundred kilobases away [6]. It is not yet known how the broken DNA ends or 
chromatin environment signal for H2A phosphorylation to occur[5]. However, it is 
known that this phosphorylation event leads to a complex and poorly understood 
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signaling cascade that engages a 5’ to 3’ exonucleolytic complex consisting of 
MRE11, Rad50, and Nbs1 (MRN complex) to process DNA ends into a format that 
is amenable to repair[4]. After processing by the MRN complex, either of two 
highly-conserved pathways is used to repair the DNA break. Remarkably, the time 
from when a cell experiences a break until H2A phosphorylation occurs is on the 
order of seconds[7]. The speed with which a DSB is detected and the amplification 
in signal that occurs following DSB recognition are a testament to the catastrophic 
consequences that an unrecognized DSB can have on a cell. 
 
I.2c: Repairing a DSB 
Perhaps the best characterized mechanism for DSB repair, non-homologous 
end joining (NHEJ) relies upon the reformation of juxtaposed broken phosphodiester 
bonds (Figure 1.2b). In mammals, this pathway is used to repair DSBs incurred by 
mutagenic insults including those sustained during V(D)J recombination. The 
mammalian NHEJ machinery found in most cells is composed of the Ku heterodimer 
(Ku70 and 86 subunits), DNA-PKcs, Artemis, Polynucleotide Kinase (PNK), 
Cernunnos, XRCC4, and Ligase IV,  (reviewed in [8, 9]). The first event in NHEJ is 
the binding of the Ku heterodimer to broken DNA ends. After Ku binds DNA, it 
recruits the kinase DNA-PKcs to the broken DNA ends. The contributions of DNA-
PKcs to NHEJ are unclear but may relate to its ability to bridge DNA ends [10, 11]. 
Its significance in NHEJ is clear, however, and is best illustrated by DNA-PKcs 
mutations that result in severe combined immunodeficiency (SCID) due to the 
 19
inability to perform NHEJ during V(D)J recombination [12]. The DNA-PKcs:Ku 
complex then recruits the Artemis exonuclease and PNK to create ligatable DNA 
ends. Finally, DNA Ligase IV and its stimulatory cofactors XRCC4 and Cernunnos 
perform the final step of forming new phosphodiester bonds [13]. During NHEJ it is 
possible for a few nucleotides to be lost from the free ends due to nucleolytic 
degradation. Since NHEJ simply religates free ends and does not have the ability to 
sense loss of information, the process is sometimes error prone. Thus, cells have a 
second error free pathway that can be used to repair DSBs when sister chromatids 
are available [14]. 
 Best known for its role in the repair of DSBs induced during meiotic 
recombination, homologous recombination provides an error-free alternative to 
NHEJ for DSB repair (Figure 1.2a). In homologous recombination, the double-strand 
break is resected by the MRN complex (Mre11-Rad50-Nbs1), yielding two single-
stranded overhangs. These overhangs are then bound by the RecA homologue Rad51 
and associated proteins, including Rad52, Rad54, Rad57, BRCA1 and BRCA2 
(reviewed in [15]). These proteins work together through a complicated and poorly 
understood sequence of events to ensure that the single-stranded 3’ overhangs invade 
and identify of homologous regions on the sister chromatid [15]. After a region of 
homology common to the DNA break and sister chromatid has been identified, base-
pairing between complementary strands allows for stabilization of this structure. 
Critically, the 3’ end of the invading strand can now be used to initiate DNA 
synthesis with the complementary intact strand as a template. DNA synthesis at this 
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stage results in 4-way intermediates called Holliday Junctions (HJ). These junctions 
are resolved by an HJ resolvase[16], and after further processing the end result is 
restoration of genetic information within the previously damaged chromosome. This 
type of repair is considered error-free because no information is lost after repair is 
completed, and occurs during S and G2 phases of the cell cycle when sister 




Figure 1.2. DNA double strand break repair pathways in mammals. (a) Homologous 
Recombination Repair Pathway. (b) Non-Homologous End Joining Pathway. 




































I.3: Naturally occurring chromosome ends are shielded from DNA repair 
 Studies of transposition events in maize and irradiated Drosophila 
melanogaster, pioneered by Barbara McClintock and H.J. Muller, respectively, 
showed that double strand breaks are efficiently repaired by the cell. Thus, each of 
these scientists were surprised by the observation that, although DSBs could be 
joined to other DSBs efficiently creating myriad combinations of translocations, 
naturally occurring chromosome termini never participated in this process[18, 19]. 
Since naturally occurring chromosome ends, which Muller called “Telomeres”, were 
hypothesized to look to the cell like de novo double strand breaks, it was surprising 
that new breaks were not joined to the native ends. This observation led McClintock 
and Muller to hypothesize that telomeres contain some mechanism that makes them 
refractory to DNA repair. 
 
I.3a Repetitive DNA at Chromosome Termini 
 Since these initial studies, modest progress has been made in understanding 
how mammalian telomeres prevent the DNA repair machinery from acting on them. 
Much of this progress has depended upon the identification of elements that are 
unique to telomeres. The first element to be recognized as essential for telomere 
function is the short, repetitive sequence of DNA found at the ends of most 
eukaryotic chromosomes. Repetitive DNA at chromosome ends was first identified 
in the ciliate Tetrahymena thermophila, and has since been found in all eukaryotes 
studied to date [20]. In vertebrates, telomeres consist of double-stranded 5’ 
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TTAGGG 3’ perfect repeats that terminate in a 3’ single-stranded overhang of the 
same sequence [21, 22]. The double-stranded regions of telomeres range in size from 
~1-100 kb, while the single-stranded regions are usually a ~10-500bp. However, 
neither the telomeric sequence itself nor the single-strand overhang are intrinsically 
refractory to DNA repair, as telomeric DNA and telomeres containing intact 
overhangs can be processed by the DNA repair machinery both in vitro and in vivo 
[23-25]. These results are important, as it has been shown that the G-rich strand of 
telomeres can adopt a special conformation called a G-quadruplex, involving non-
Watson-Crick base pairing between four juxtaposed guanine residues coordinated by 
monovalent cations [26]. Data indicating that telomeric DNA can be joined by the 
DNA repair machinery suggests that either telomeres do not adopt G-quadruplex 
conformations regularly, or that this structure by itself does not inhibit repair.  
It is important to note that the telomeric sequence is critical for telomere 
function. Evidence of stringent sequence-specific requirements for telomere end 
protection comes from organisms that have been manipulated to produce telomeres 
with mutated sequences [27, 28]. In these organisms, which include yeasts, ciliates, 
mice and humans, mutated telomeres invariably result in telomere deprotection [27-
30]. Therefore, the question becomes: how does the sequence specificity of telomeric 





I.3b: Telomeric Proteins bind DNA in a Sequence-Specific Manner 
The ability of DNA-binding proteins to bind DNA in a sequence specific 
manner is ubiquitous in biology, with examples from the simplest bacteriophage to 
the most complex cell [31, 32]. Thus, early models of telomere protection suggested 
that unknown factors may bind in a sequence-specific manner to telomeres and 
prevent DNA repair proteins from acting aberrantly at chromosome termini. This 
hypothesis provided the impetus for the isolation of the first telomere binding 
protein, the Oxytricha nova Telomere End Binding Protein (TEBP-α), in the 1980s 
[33]. TEBP was shown to bind the single-strand overhang at telomeres and protect it 
from nucleolytic degradation. Studies of TEBP and homologues such at the 
Protection of Telomeres-1 (POT-1) protein indicated that end binding proteins are 
essential for normal telomere maintenance, as loss of function of TEBP homologues 
leads to telomere deprotection, dysfunction, and fusion [34-36]. The discovery of 
TEBP also signaled a shift from the study of telomeric DNA to telomere binding 
proteins 
 The identification of the first vertebrate telomere binding protein, telomere 
repeat binding factor 1 (TRF1)[37], was one of the biggest fruits of this change in 
emphasis. TRF1 was identified based on a DNA binding activity in human cell 
extract that has high affinity and specificity for double-stranded TTAGGG repeats. 
TRF1 has an acidic stretch of ~100 amino acids at its N-terminus whose contribution 
to telomere maintenance is unknown (Figure 1.3e). The C-terminus contains a well-
characterized Myb-like domain, which is structurally related to homeodomain 
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transcription factors [38]. Unlike its homeodomain-containing family members, the 
TRF1 Myb domain exhibits a strong preference for the sequence 5’YTAGGGTTR3’, 
providing the specificity necessary to localize to and bind telomeres [39]. The middle 
region of TRF1 contains the TRF homodimerization domain (TRFH), and both the 
TRFH and Myb have been crystallized and studied in great detail. The TRF 
homodimerization domain binds another TRF1 molecule to promote formation of a 
DNA-binding competent homodimer, since Myb domains require dimerization for 
DNA binding [40].  
The binding of TRF1 to telomeres is thought to regulate telomere length 
maintenance, as overexpression of TRF1 leads to telomere shortening while 
inhibition leads to longer telomeres [41]. Importantly, it has also been shown that 
recruitment of TRF1 to lacO sites embedded within an engineered telomere results in 
shortening of the targeted telomere. This result demonstrates that additional domains 
besides the DNA binding domain within TRF1 contribute to cis-regulated functions, 
a theme that is common among telomere binding proteins [42]. Finally, TRF1 has 
been implicated in the cohesion of sister telomeres during and after DNA replication 
[43, 44]. Recent studies have identified telomere-specific cohesion complexes that 
pair sister telomeres during mitosis [43, 45]. Aberrant regulation of sister telomere 
cohesion was shown to result in NHEJ-dependent sister telomere fusion, suggesting 
that TRF1 may indirectly contribute to telomere protection by ensuring proper 
telomere separation [45]. The ribosylation of TRF1 was shown to facilitate 
separation of sister telomeres, suggesting that TRF1 contributes to genome stability 
 26
and telomere protection by ensuring that telomeres are segregated properly during 
mitosis [44]. However, loss of TRF1 function is not associated with an increase in 
DNA repair at telomeres or growth delay [46], indicating that its contribution to 
telomere protection may be minor or is masked by other telomere binding proteins.  
 Two years after the discovery of TRF1, two groups independently identified 
TRF2 [47, 48]. One of the most studied telomere binding proteins identified to date, 
TRF2 has roles in numerous processes including telomere protection, DNA repair, 
and transcriptional activation[49-51]. Similar to TRF1, TRF2 has a C-terminal Myb 
domain and a TRFH domain between amino acids 89-200 (Figure 1.3e). TRF2 binds 
telomeric DNA with high affinity and specificity in vitro, and resides at telomeres in 
vivo [48, 52]. However, unlike TRF1, TRF2 has a basic region at its N-terminus.  
This region has gained notice recently due to the presence of several glycine and 
arginine residues, which are common in RNA binding proteins, suggesting that 
TRF2 may bind RNA. 
The roles of TRF2 in telomere protection were demonstrated in a series of 
groundbreaking experiments from the laboratory of T. de Lange [53, 54]. In these 
experiments, the de Lange group expressed truncated versions of TRF2 and observed 
distinct types of telomere dysfunction resulting from deletion of either the basic or 
Myb domains. Amazingly, TRF2 fragments lacking the basic or Myb domains 
resulted in increased HR and NHEJ at telomeres, respectively, suggesting that TRF2 
has multiple roles at telomeres [53, 54]. Deletion of the N-terminus of TRF2 leads to 
homologous recombination-dependent telomere hyper-recombination and hinders 
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replication fork progression through telomeres, which identifies a role for TRF2 in 
facilitating telomere replication that is discussed in detail later in this thesis [54-56]. 
Exactly how this domain promotes telomere replication is not known, and is an 
exciting and unexplored area of telomere biology. 
In contrast to the telomere-HR phenotype associated with TRF2ΔB 
expression, expression of Myb-domain deletions of TRF2 result in NHEJ-dependent 
telomere fusions [25, 53]. This allele is hypothesized to work by dimerizing with 
endogenous TRF2, creating a DNA-binding incompetent heterodimer. In accordance 
with this hypothesis, expression of TRF2 fragments lacking the Myb domain lead to 
a reduction in the amount of endogenous TRF2 at telomeres [53, 57]. Further 
supporting a role for TRF2 in telomere protection, loss of TRF2 from telomeres is 
associated with increased ATM kinase signaling and DNA repair processing at 
telomeres, and another report has shown that TRF2 can directly bind and inhibit the 
ATM kinase [58, 59]. Finally, a recent study has shown that TRF2 binds 
unphosphorylated Chk2, which is a downstream target of ATM, potentially further 
inhibiting damage signaling at telomeres [60]. Despite these results, the mechanism 
or mechanisms TRF2 employs to inhibit NHEJ at telomeres is still not known. 
The idea that telomere binding proteins work not just by binding telomeres, 
but by carrying out functions using other domains within these proteins suggested 
that TBPs may recruit other proteins to telomeres. The search for TRF1 and TRF2-
interacting factors has yielded a long list of interacting factors including 
exonucleases[61], poly-ADP-ribosylases [62], transcription factors [49], DNA repair 
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proteins [59, 63], and other telomere maintenance factors [64, 65]. The exact 
contributions of these accessory proteins to telomere protection are still not known. 
 Although TRF2 has been shown to interact with myriad different factors, 
perhaps the strongest interaction between an interacting factor and TRF2 is the 
RAP1 protein, which is supported by both biochemical and genetic data [65, 66]. 
hRAP1 was first identified in a yeast two hybrid screen for TRF2 interacting factors, 
and was named based upon limited sequence homology to the budding yeast 
Repressor-Activator Protein 1 [65]. Initial studies of the 399 amino acid protein 
indicated that it contains several domains, including an N-terminal BRCT domain 
that is expected to bind an unknown phosphorylated protein, as well as a single 
internal Myb domain (Figure 1.3e). Studies of this Myb domain suggest that it is not 
capable of binding DNA  since the electrostatic surface of this domain is neutral, 
while Myb domains from DNA-binding competent proteins are positively charged 
allowing them to interact with the negatively charged DNA backbone [67]. hRAP1 
also contains a coiled-coil domain of unknown function, and a C-terminal region that 
is conserved between RAP1 homologues. This region is an important protein-protein 
interaction domain for RAP1, as it mediates the interaction of hRAP1 and hTRF2 in 
humans, and ScRAP1 and ScRIF1, ScRIF2, and ScSIR4 in budding yeast [65, 68]. In 
support of the idea that the C-terminus of RAP1 homologues is critical for its 
function, deletion of 60 amino acids near the C-terminus (271-330) resulted in an 
hRAP1 fragment that did not localize to telomeres [66, 69]. When combined with 
data demonstrating that loss of TRF2 from telomeres results in concomitant 
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delocalization of hRAP1 as well, it is clear that hRAP1 requires TRF2 for its 
localization. 
Though similarities exist between hRAP1 and ScRAP1, as noted above, 
numerous differences are readily apparent. Most importantly, while hRAP1 can not 
bind DNA directly, budding yeast RAP1 directly binds DNA, alleviating the need for 
a TRF2 homologue to recruit it to telomeres. In addition to differences in DNA 
binding ability, hRAP1 localizes exclusively to telomeres while ScRAP1 is present 
at telomeres and in the promoters of ~5% of budding yeast genes [70]. Also, 
ScRAP1 interacts with many different proteins, including ScRAP1 interacting 
factors ScRif1 and ScRIF2, and ScSIR4 [71, 72]. No homologues of these proteins 
have been identified in humans, further demonstrating the divergence between 
hRAP1 and ScRAP1. This data suggests that ScRAP1 and hRAP1 have diverged 
significantly since their last common ancestor and that their functions may not 







Figure 1.3. (a-d) Telomeric DNA sequence and associated proteins in different 
species of eukaryotes. (e) Domain structures of three human shelterin components. 
Reprinted, with permission, from the Annual Review of Genetics, Volume 42 © 2008 
by Annual Reviews   www.annualreviews.org
 
I.3c: Do ScRAP1 and hRAP1 carry out functions that are conserved between 
species?  
Interestingly, ScRAP1 is a critical mediator of NHEJ inhibition at telomeres 
in budding yeast, and RAP1 loss from the distantly related fission yeast S. pombe 
also results in NHEJ-dependent telomere fusions, further implicating RAP1 in 
protecting telomeres from NHEJ [24, 68, 73]. Only ScRAP1’s role in NHEJ 
inhibition has been characterized, though. Recent data suggests that ScRAP1 serves 
as a protein hub that recruits two factors that work independently to inhibit NHEJ at 
telomeres, ScRIF2 and ScSIR4 [68]. Each of these factors inhibits NHEJ using 
unknown mechanisms, as concomitant deletion of ScRIF2 and ScSIR4 results in 
more telomere fusions than deletion of either gene alone. ScRAP1 may be more than 
just a protein hub, however, since a central region in ScRAP1 also contributes to 
NHEJ inhibition at budding yeast telomeres independently of ScRIF2 and ScSIR4 
[68]. The tripartite model for NHEJ inhibition at telomeres has yet to be 
demonstrated in other eukaryotes and may not be relevant to metazoans since no 
ScRIF2 or ScSIR4 homologues have been identified in these species.  
Because loss of RAP1 function in the distantly related budding and fission 
yeasts leads to telomere deprotection, it was surprising that hRAP1 has not been 
shown to play such a role at human telomeres. Previous work failed to effectively 
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disrupt hRAP1 function, leaving its role in telomere protection unaddressed [66, 69]. 
Moreover, gene targeting in mice is complicated by the presence of a bidirectional 
promoter that also transcribes a putatively essential lysyl tRNA synthetase [74]. 
Overexpression studies with full length hRAP1 and a series of hRAP1 truncations 
suggested that it plays a role in establishing telomere length since hRAP1 
overexpression led to an increase in telomere length heterogeneity[66]. Although this 
is the only reported function for hRAP1, hRAP1’s exact contribution to telomere 
length maintenance is not known. Surprisingly, a TRF2/hRAP1 complex was 
demonstrated to be required for protecting telomeric DNA ends from end-joining in 
an in vitro NHEJ assay, suggesting that hRAP1 may contribute directly to telomere 
protection [23]. To date, no evidence for hRAP1 in NHEJ inhibition at telomeres in 
vivo exists, though the ascertainment of such evidence is of high interest to the 
telomere field [75]. Therefore, the search for hRAP1’s function in vivo, including its 
potential contribution to telomere protection, remains an important area of research 
in the telomere field and is the subject of Chapter Three of this thesis. 
 
I.3d: TBPs and telomeric sequence may work in concert to protect chromosome ends 
Numerous studies have reported loop-like structures at chromosome ends in 
electron micrographs prepared from different eukaryotes, including humans (Figure 
1.4) [76-78]. These loops are hypothesized to occur when the terminal single-
stranded overhang invades the adjacent double-stranded region, causing 
displacement of the G-rich strand into a structure called a D-loop. Such structures are 
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reminiscent of HR intermediates. The entire loop structure has been termed a t-loop 
(telomere loop), and has been hypothesized to contribute to telomere protection 
because the end of the 3’ overhang would be protected against nucleolytic attack 
when buried within the t-loop. TRF2 has been shown to promote t-loop formation in 
vitro [79, 80]. Also, the basic domain of TRF2, which may inhibit HR at telomeres, 
was shown to be necessary for TRF2-mediated t-loop formation [79]. Thus, loss of 
TRF2 from telomeres may compromise t-loop formation in vivo. This observation 
may explain the telomere fusion phenotype observed upon loss of TRF2 from 
telomeres. It is important to note that no data on the protective function of t-loops at 
telomeres has been reported, even though ample opportunity for the ascertainment of 
such data exists given that t-loops have been found in many species including 
trypanosomes, humans, yeasts, plants, and ciliates [77, 78, 81, 82]. Also noteworthy 
is the fact that t-loops have only been observed under conditions that are not 
amenable to life, since t-loop visualization requires either protein:DNA or DNA 
inter-strand crosslinking for stabilization [76, 78]. The artificial stabilization required 
to preserve and visualize t-loops suggests that they may be ephemeral structures in 
vivo, which would not be commensurate with a major role in telomere protection. 
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Figure 1.4: T-loop observed in electron microscopy samples prepared from HeLa 
I.2.11 DNA [76]. Copyright Elsevier 1999. 
 
Though the identification of single-and double-stranded TBPs and t-loops 
suggest intriguing models for telomere protection, neither addresses a poorly 
understood conundrum; why loss of double-stranded telomere binding proteins leads 
to NHEJ at telomeres. As stated previously, telomeres terminate in a single-stranded 
region that is bound by TEBP homologues including POT-1. Because the NHEJ 
machinery needs free DNA ends on which to load, the presence of POT-1 on 
telomeric overhangs may block the MRN and Ku complexes from accessing DNA 
ends. It is possible that TRF2 regulates or modulates POT1 binding to DNA [83, 84]. 
However, since POT-1 knockout mice display a very mild telomere fusion 
phenotype, the roles of POT-1 and associated factors in NHEJ inhibition at telomeres 
remain unknown [85, 86]. 
Despite the single-strand overhang, the loss of double-stranded telomere 
binding proteins from telomeres results in NHEJ-dependent telomere fusions in a 
variety of species. In addition, other reports have demonstrated that very short 
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telomeres with few TBP binding sites can become fusogenic, leading to covalent 
telomere fusions [87-89]. Because pre-neoplastic cells display chromosomal fusions 
with critically short telomeres at the fusion site[87], understanding how telomeres 
shorten and what distinguishes a critically short, fusogenic telomere from a 
functional one are of utmost interest to the telomere field and cancer biology.   
 
 I.4: Telomere Replication 
 The machinery that executes semiconservative DNA replication is highly 
conserved among eukaryotes. In eukaryotic DNA replication, an origin recognition 
complex consisting of origin recognition complex (ORC) subunits 1-6 binds origins 
of replication on chromosomes in the G1-phase of the cell cycle. The binding of 
ORC to replication origins mediates recruitment of other factors, including Cdc6, 
Cdc45, Cdt1, and MDM 2-7, which all work together to license the replication origin 
for firing (reviewed in [90]). It is important to note that while budding yeast has 
sequence-specific recruitment of ORC to replication origins, ORC recruitment in 
humans appears to be sequence independent [90]. The factors that mediate ORC 
recruitment to human replication origins remain unknown. Upon recruitment of 
DNA polymerase α, primase, RPA, and associated factors, replication fork 
progression occurs in the 5’ to 3’ orientation. This polarity is due to the ability of 
DNA polymerases to catalyze phosphodiester bond formation between nucleotide 
triphosphates with phosphate groups attached to the 5’ position on sugars and DNA 
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polymers with an available hydroxyl group at the 3’ position on the sugar for 
phosphdioester bond formation.  
 The anti-parallel configuration of complementary DNA strands renders 
symmetrical DNA synthesis impossible.  To circumvent this issue, cells employ 
asymmetric DNA replication. This means that at replication origins the strand to be 
synthesized continuously in the 5’ to 3’ direction is copied first. The displacement of 
the complementary strand by the newly synthesized “leading” strand allows for 
initiation of 5’ to 3’ DNA synthesis of the “lagging” strand, which is synthesized 
discontinuously in segments called Okazaki fragments.   
 
I.4a: The end-replication problem 
Since DNA polymerases use an RNA primer to initiate synthesis, and must 
synthesize DNA in the 5’ to 3’ direction, excision of the RNA primer at the 5’ end 
yields a gap in the DNA that is usually filled in by initiating synthesis from adjacent 
Okazaki fragments. However, when the terminal 5’ RNA primer is removed, no 
upstream lagging strand DNA is available to initiate “fill in” synthesis from, yielding 
a single-stranded DNA end. Thus, the lagging strand ends of each chromosome are 
shorter than their templates. Eventually, this shortening due to incomplete end 
replication would lead to loss of critical regions in chromosomes such as essential 
genes or structural elements that are necessary for cell function. If unchecked, this 
problem would result in the extinction of any species—eukaryotic or prokaryotic—
with linear chromosomes. The “end replication problem” (Figure 1.5), as was 
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independently hypothesized by Jim Watson and A. Olovnikov in the 1970s, is one of 
the most fundamental and interesting problems in biology [91, 92]. 
Leading Strand Synthesis 
Lagging Strand Synthesis 
Removal of RNA primer (red) 
creates ss gap at end 
Leading Strand Synthesis 
Degradation of C-rich Strand 
G-overhang Elongation by Telomerase 
Semi-conservative DNA Synthesis 
Removal of RNA primer (red) recreates G-
overhang 
 
Figure 1.5: (a) Representation of the “end replication problem”. (b) Generation of 
single-stranded overhangs and elongation by telomerase counteracts the “end 




I.4b: Telomerase counteracts the end-replication problem 
 Of course, since all eukaryotes have linear chromosomes, these cells must 
contain a mechanism to counteract the end replication problem. The ingenious 
solution in most cases is provided by a reverse-transcriptase enzyme called 
telomerase [94]. This enzyme is comprised of both protein and RNA components, 
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and uses an RNA primer contained within the RNA component to add nucleotides to 
the ends of chromosomes during S-phase. In vertebrates, for example, telomerase 
invariably adds repeats of the sequence TTAGGG to chromosome ends, which 
extends the template that can be used for synthesis of the complementary strand and 
allows for fill-in synthesis of the lagging strand. Thus, telomerase counteracts the 
loss of DNA associated with lagging strand synthesis that would normally occur with 
each division.  
 The impact of telomerase on individual cells was illustrated in an important 
set of experiments by Shay, Wright, Harley and colleagues in the 1990s. It had been 
previously shown that telomerase-negative primary fibroblasts divided a definite 
number of times before ceasing to proliferate [95]. This phenomenon, ascribed to 
dysfunctional telomeres resulting from the end replication problem associated with 
each round of cell division, has been termed the “Hayflick Limit”. Shay, Wright and 
Harley demonstrated that reconstitution of telomerase activity in primary fibroblasts 
extended the lifespan of primary cells indefinitely [96], suggesting that telomere 
shortening was responsible for the finite lifespan of primary cells. This data also 
supports a role for telomeres in organismal aging, whereby cells in tissues can only 
divide a certain number of times before succumbing to the effects of a critically short 
telomere [97].  
 The importance of telomerase to organisms has been demonstrated in a wide 
range of species from budding yeast to man. In every species that relies upon 
telomerase-mediated telomere lengthening, loss of telomerase activity results in loss 
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of organismal viability [98-101]. Most importantly, the loss of viability is anticipated 
by the average telomere length of the affected individual. For example, telomerase 
null mice with telomere length distributions of ~10-80kb are indistinguishable from 
their wildtype littermates, while telomerase null mice with much shorter telomere 
length distributions (~0-50kb) are not viable [100]. Because mice with longer 
telomeres have plenty of telomeric DNA in reserve to counteract the end replication 
problem, these mice survive without telomerase for many generations. Remarkably, 
this trend is also observed in the human progeroid disease Dyskeratosis Congenita 
(DKC), which can be caused by mutations in telomerase [101, 102]. DKC patients 
demonstrate a phenomenon called “anticipation”, whereby the onset of the disease is 
anticipated by telomere length of the diseased individual [102]. 
 Though the end-replication problem seems like quite a challenge to surmount 
in order to have larger genomes, it does have at least one benefit. In complex 
multicellular organisms such as mammals, most differentiated cells do not divide. 
Instead, these cells carry out their functions and then eventually die, without giving 
rise to a progenitor. In addition, these cells do not express enough telomerase to 
counter-act the end-replication problem [103]. An example of such cells is neurons, 
which do not divide, express little if any telomerase, and carry out their specified 
function for as long as possible before succumbing to any of a variety of insults 
[104]. However, in rare cases, cells such as differentiated neurons receive aberrant 
signals to start dividing uncontrollably. These precancerous cells extinguish 
themselves if they do not reactivate telomerase [105], as with each aberrant cell 
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division their chromosome ends become shorter, until they are no longer functional. 
This has been observed in mice lacking telomerase, providing evidence for the end-
replication “problem” as a tumor suppressor mechanism [106]. Related to this, 
telomerase inhibition may also prevent uncontrolled proliferation of cancerous cells, 
and numerous pharmaceutical companies are developing anti-telomerase 
therapeutics. 
 
I.4c: Some transformed cells can divide indefinitely without telomerase  
 This question was first postulated by Reddel and colleagues in 1996 [107], 
when they made the observation that certain immortalized human cancer cell lines do 
not express telomerase. Since their observation, studies in organisms ranging from 
yeast to worms to human cells have identified alternative pathways of telomere 
maintenance [107-109]. In human cells, one pathway of telomerase-independent 
telomere length maintenance has been identified, called alternative lengthening of 
telomeres (ALT) [110]. Though it is not known how cells engage this pathway, 
human cancers can use ALT-related mechanisms to counteract the end-replication 
problem[111]. Remarkably, in some cancer types such as leiomyosarcomas, 
approximately 77% of tumors rely on ALT, where as in rhabdomyosarcomas, only 
6% of cells use this pathway [111]. It is still unclear why different cell types display 
very different propensities for engaging this pathway. However, numerous studies 
have identified events that are associated with the transition to ALT status, as well as 
genes important for ALT[110, 112-114]. One important factor that may be involved 
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in ALT development is the pro-myeloid leukemia (PML) body, as its association 
with telomeres in ALT cell lines has been well documented [115-117]. Though these 
bodies are poorly understood, they may function to facilitate recruitment and 
stimulate activities of certain proteins involved in homologous recombination, which 
is the very same pathway used for DNA DSB repair and described earlier. In fact, 
ALT appears to rely on homologous recombination-directed DNA synthesis to 
facilitate lengthening of critically short telomeres. Such a pathway for telomere 
maintenance is a demonstration of the intricate relationship between telomere 
maintenance and the DNA repair machinery. 
 
I.4d: Replication through repetitive DNA that can form non-canonical structures 
 Another problem posed by telomeres is their ability to adopt structures that 
have been shown, either in vitro or in vivo, to hinder DNA replication (Figure 1.6). 
For example, the guanine residues in TTAGGG repeats can form non-Watson Crick 
base pairs, leading to G-quadruplex structures that have been observed in vivo [26]. 
It is thought that these structures disrupt replication fork progression due to intra-
strand base pairing [118]. To counteract this problem, vertebrates contain highly 
conserved RecQ-like helicases, including WRN and BLM, that can relax such 
structures. WRN localizes to telomeres in S phase, and promotes replication of G-
rich lagging strands [119, 120]. In addition, helicase-dead mutants of WRN had an 
increase in stalling of replication forks at telomeres, and loss of G-rich lagging 
strands, further implicating WRN in this process. Remarkably, mutations in WRN 
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have been linked to the progeroid disease Werner’s syndrome, suggesting that 
defects in telomere replication play a role in aging [121]. This disease further 
illustrates the importance of proper telomere replication in both cellular and 
organismal viability  
 G-quadruplexes are just one potential hindrance to telomere replication. 
Telomeres also consist of densely packed heterochromatin, which means that 
telomeric nucleosomes are packaged together more tightly than other nucleosomes 
within the cell, which could restrict access of the replication machinery to telomeres 
[122, 123]. Recent research suggests that double-stranded telomere binding proteins, 
including TRF2 in mammals and Taz1 in fission yeast, may recruit the origin 
recognition complex to telomeres [55, 124, 125]. If TRF2 indeed recruits ORC to 
telomeres, this recruitment would be independent of nucleosomes, since TRF2 
interacts with DNA directly, therefore abrogating the difficulties associated with 
ORC finding appropriate replication origins buried in telomeric DNA. 
 As was stated previously, telomeres can adopt specialized structures called t-
loops. Though it is possible that these structures could shield telomeres from 
recognition by the DNA damage machinery, they would undoubtedly also block 
replication fork progression. Thus, they would need to be resolved during S-phase 
for telomere replication to occur. How these structures are resolved in S-phase is not 
known, but may relate to the ability of TRF2 to recruit RecQ helicases like BLM and 
WRN to t-loops [126, 127], where they could be unwound before a replication fork 
encounters them. It is possible that the telomere dysfunction associated with 
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expression of a helicase dead mutant of WRN could be linked to the inability of the 
helicase dead mutant to unwind t-loops[120], though that model is purely speculative 
at this time.  
 
I.4e: Consequences of Improper Telomere Replication 
 While the search for telomere dysfunction phenotypes associated with 
improper telomere replication in mammals has been limited to the identification of 
telomere recombination with subsequent production of t-circles, work in fission yeast 
has suggested that dynamic interchromosomal telomere associations can result from 
improper telomere replication [128]. Because stalled replication forks are efficiently 
repaired by homologous recombination using the newly synthesized sister chromatid 
as a template, most stalled forks are not particularly harmful to the cell. On the 
contrary, when telomeric DNA is present in a stalled replication fork, two problems 
occur. First, since all chromosome ends contain telomeric DNA, any chromosome 
end could be used as a template for repair, and any homologous region within that 
chromosome end could be used, leading to the unequal exchange of DNA between 
these two chromosomes. Second, the special structures that telomeres adopt, 
including G-quadruplexes, may be aberrantly processed by RecQ helicases during 
HR, yielding unrepaired joint molecules that persist through the cell cycle [128]. The 
end result of this process is that telomeres can become “entangled”, as has been 
observed in fission yeast [129]. Interestingly, these telomere entanglements have 
been linked to both the ability of the TRF2 homologue taz1 to promote proper 
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telomere replication, as well as the WRN homologue rqh1 to improperly process 
telomeric Holliday junctions [125, 128]. These results strengthen the idea that 
telomere replication poses unique challenges to the replication machinery and 
illuminate the importance of proper telomere replication in the life cycle of a cell. 
Chapter Four describes the identification of a novel phenotype associated with 





Figure 1.6: Problems associated with replication of telomeres during DNA 
synthesis. Reprinted with permission from Nature Publishing Group.  
 
 
I.5: Scope of Dissertation 
 The primary goal of the research conducted during my tenure as a graduate 
student is to understand the intricate relationship between DNA repair and telomere 
maintenance. Since the DNA repair machinery consists of multiple complex 
pathways that are difficult to analyze in concert, we sought to establish a new 
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paradigm for studying the relationship between telomeres and DNA repair by 
investigating the mechanisms that telomeres employ to locally inhibit the NHEJ 
machinery. By dissecting the precise contributions of several telomere binding 
proteins and associated factors to NHEJ inhibition at telomeres, we have uncovered 
novel roles for hRAP1 and TRF2 in telomere protection in humans. The results of 
this research are reported in Chapter Three of this thesis.  
 In addition, during the course of our research on requirements for NHEJ 
inhibition at telomeres, we identified a previously unreported phenotype associated 
with telomere dysfunction in human cells. Characterization of this phenotype 
suggests that it is very different from previously reported phenotypes associated with 
telomere dysfunction, especially the well-characterized covalent NHEJ-dependent 
telomere fusions observed upon loss of TRF2 from telomeres [25, 53, 58, 130, 131]. 
Instead, we present evidence demonstrating that this new type of telomere 
dysfunction is associated with replication stress at telomeres, and may result from 
aberrant homologous recombination. The results and implications of its significance 
are presented in Chapter Four of this thesis. 
Chapter Two of this dissertation contains a comprehensive list of the 
materials and methods used to execute the studies described in subsequent chapters. 
Chapter Five provides a summary of the results presented in Chapters Three and 
Four. In addition, Chapter Five also provides a synthesis of the information 
presented in Chapters Three and Four with current literature. Finally, this chapter 
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describes numerous future directions for research that build upon the studies reported 












































Materials and Methods 
 
II.1: Polymerase Chain Reaction (PCR) 
High-fidelity DNA polymerase HotStart PfuTurbo (Stratagene) was used for 
all reactions since PCR was only used for the purposes of cloning cDNAs into 
vectors for expression in either bacterial or mammalian systems.  The components of 
the 50μL PCR reactions were as follows: 0.5μM of each DNA oligonucleotide 
(Integrated DNA Technologies, IDT) (usually containing 24-27bp of complementary 
bases); 0.2mM dNTPs; 5μL of 10X Pfu Buffer (Stratagene); 1μL of template (DNA 
mini or maxipreps diluted ~1:100, or 1μL of first-strand cDNA from fission yeast 
provided by K. Trujillo); 1μL of PfuTurbo Hot Start Polymerase (Stratagene); ddH20 
to 50μL. The PCR reactions were carried out in either an ABI 2400 thermocycler or 
an Eppendorf EP mastercycler as follows: after 3min at 94oC, 30 cycles of 94 oC for 
30s, 55 oC for 45s, 72 oC (time=60s for every kilobase to be amplified, such that a 
2kb fragment was incubated for 120s) were performed. Following the 30 cycles, an 






II.2: Purification of PCR fragments 
 For gel purification, 50μL of the PCR reaction was run on an agarose gel, 
excised with a razor under UV light (280nm), and placed in a 2.0mL tube. The 
fragment was then weighed and processed using the Qiagen Gel Extraction Kit 
according to the manufacturer’s instructions, except that a 5 minute incubation in 
buffer PE was always performed. For direct purification of the PCR product without 
gel purification, the Qiagen PCR Purification Kit was used according to the 
manufacturer’s instructions, except that a 5 minute incubation with buffer PE was 
always employed. 
 
II.3: Restriction Enzyme Digestion 
 All restriction enzymes used in these studies were purchased from New 
England Biolabs. For analytical restriction digestion of miniprep-purified plasmid 
DNA, 2μL of DNA (~200-300ng/μL) was incubated with the appropriate NEB 
buffer (10X stock), restriction enzyme(s), and if necessary 100μg/mL bovine serum 
albumin (BSA), in a final reaction volume of 15μL for 1-18hr at 37  oC. Digests 
incubated <3hr were placed in a water bath, while longer digests were incubated in a 
dry incubator. The volume of total restriction enzyme(s) added to the reaction was 
always 10%, such that 1.5μL of one enzyme was added to a single digest, or 0.75μL 
of two enzymes, or 0.5μL of three enzymes were added. BSA was added from a 10X 
stock such that 1.5μL was added to the reaction. For preparative digests using either 
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gel-extracted or PCR-purified DNA, 30μL of these reactions were digested with 5μL 
of the appropriate 10X NEB buffer, 100μg/mL BSA if necessary, and either 5μL of 
one restriction enzyme of 2.5μL of each of two restriction enzymes in a final 
reaction volume of 50μL. Reactions were incubated identically to the conditions 
listed for analytical scale digests. Finally, for preparative restriction digests of 
plasmids, 2μg of plasmid was digested in a 50μL final volume, otherwise the other 
components of the reaction are identical to those listed for preparative digest of PCR 
products. When necessary, 1μL of Calf Intestinal Phosphatase (New England 
Biolabs) was added to the restriction digest for 30 minutes to dephosphorylate DNA 
ends, thereby preventing self-ligation. 
 
II.4: Ligation of DNA 
 For T4 DNA Ligase ligation, reactions were carried out in a final volume of 
10μL. In these reactions, 3μL of the DNA fragment to be inserted (obtained either by 
PCR followed by Gel or PCR purification, or a DNA fragment obtained by digestion 
of another plasmid) was incubated with 1μL of the receiving vector, 1μL of hand-
thawed 10X T4 DNA ligase buffer (NEB), and 4μL of ddH20. After a 2 minute 
incubation at 37 oC, 1μL of T4 DNA ligase (NEB) was added, and the reaction was 
incubated at room temperature for 2-4hr, followed by overnight incubation at 15oC if 
directional cloning (cloning of fragments with complementary single-stranded 
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overhangs) was being performed. Negative controls simply replaced the 3μL of 
“insert” DNA with Qiagen EB. 
 For quick ligation, the amounts of DNA used for this reaction are the same as 
those used for T4 DNA ligation and the final reaction volume of 10μL is unchanged, 
also.  5μL of 2X Quick Ligase buffer was also used in this reaction, and after 
incubating the buffer and DNA at 37oC for 2 minutes, 1μL of Quick Ligase was 
added. The reaction was then incubated at room temperature for at least 5 but not 
more than 10 minutes. For negative controls, the 3μL of inserted DNA was replaced 
with an equivalent volume of Qiagen EB. 
 Ligation of blunt-ended PCR products into pCR4-Blunt vector (Invitrogen) 
was performed as follows: 1μL of vector was incubated with 2μL of the insert to be 
cloned, 1μL of TOPO Salt Solution, and 2μL of ddH20 were gently mixed by 
pipetting and incubated for 20minutes at room temperature.  
 
II.5: Transformation 
Transformation of DNA into E. coli was performed using either of two methods: 
electroporation or heat shock. 
 
II.5a: Electroporation 
For electroporation, 0.8 μL of DNA (1X from a ligation or 1:100 from a 
plasmid prep) was added to a pre-chilled 1.0mM electroporation cuvette (VWR), 
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taking care to not touch the metal surfaces of the cuvette. Next, 40μL of 
electroporation-competent XL-1 blue cells were added to the cuvette, and the cuvette 
was recapped. Electroporation using 1.8kV with an infinite resistance and 
capacitance of 25 uF was carried out in accordance with the manufacturer’s 
directions. After electroporation, 250μL SOC media was added to the cuvette, and 
cells were removed from the cuvette, placed in a 15mL plastic tube, and incubated at 
37 oC and 250rpm for 1hr, after which they were spread (1 plate had 15μL of cells, 
the other had 200μL) onto a Petri dish containing Luria Broth agar with the 
appropriate antibiotic. The concentration of carbenicillin in LB agar was 50μg/mL, 
while kanamycin was used at 25μg/mL. 
 
II.5b: Heat-Shock 
 Heat-shock transformation for subcloning was performed with either library 
efficiency DB3.1 or OneShot TOP10 (Invitrogen). After slowly thawing cells on ice, 
1-2μL (between 1 and 100ng) of DNA sample was added, and cells were incubated 
with DNA on ice for 5min. Next, the sample was incubated at 42  oC for 30s in a 
water bath. After cooling the cells on ice for 2min, 250μL of SOC was added to the 
tube, and the tube was placed on a rotating wheel for 1hr at 37 oC. Cells were then 
spread onto an appropriate LB-agar plates with relevant antibiotic, such that one 
plate contained 20μL of the cell mix, while the other had 200μL. For protein 
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expression, either BL21 DE3(pLysS), or Rosetta cells were transformed with 10ng 
DNA in the same manner as DB3.1 or OneShot TOP10 cells, except that a 45second 
heat shock at 42 oC was used. 
 
II.6: Preparation of Plasmid DNA 
 For small-scale preparation of DNA, 2mL cultures were inoculated with 1 
colony from a freshly prepared bacterial plate 12-18hr before processing. Plasmids 
were purified using the Qiagen SpinMiniprep Kit. For DNA to be used for 
transfection, 110mL cultures were inoculated with 1 colony from a freshly streaked 
plate 15-20hr before harvesting. The harvested pellet was spun at 3000 rpm in a 
Beckman Allegra 6R centrifuge for 20min, and the pellet was then processed using 
the Qiagen EndoFree Maxi Kit according to the manufacturer’s directions, except 
that a JS-13.1 rotor (with Beckman tube 357003) was used for centrifugation, 500μL 
of EndoFree TE was used to resuspend DNA, and DNA was incubated at 65 oC for 
1min to facilitate resuspension.  
 
II.7: Agarose gel electrophoresis 
Agarose gels were poured by addition of between 0.6 to 1.8g of SeaKem 
GTG Agarose (Lonza) to 100mL of 0.5X Tris-Borate EDTA (TBE) in a 500mL 
Erlenmeyer flask, which after addition of the agarose and TBE, was weighed. After 
heating for 120s, ddH20 was readded to the original mass of the flask plus its 
contents. The slurry was then reheated for 45s, capped with aluminum foil, and 
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incubated at 42  oC for 10min before addition of 2.5μL of ethidium bromide 
(10mg/mL stock). The gel solution was then poured into a casting tray and allowed 
to cool for 1hr. The gel was run for 60min at 80V in 0.5X TBE with 15μL of 
ethidium bromide (10mg/mL stock) added to the running buffer. 
 
II.8: Cell culture 
 All mammalian cells used in this study were grown at 37 oC in a humidified 
incubator with 5% CO2 and ambient O2. For HeLa S3 (ATCC), cells were grown in 
media containing DMEM supplemented with 2mM GlutaMAX (Invitrogen), 0.1mM 
non-essential amino acids (Invitrogen), and 10% fetal bovine serum (JRH), and 
passaged at a 1:10 dilution every 3 days. GM00558 were purchased from the 
NIGMS Human Genetic Mutant Cell Repository (Camden, NJ) and grown in RPMI 
supplemented with 15% FBS and 2mM L-glutamine. GM16147 (XRCC4 null) cells 
were grown in Ham’s F12 supplemented with 10% FBS, and were split 1:7.5 every 3 
days. The WRN deficient cell line AG11395 and the normal transformed fibroblast 
VA-13 were grown in media containing DMEM supplemented with 2mM 
GlutaMAX (Invitrogen), 0.1mM non-essential amino acids (Invitrogen), and 10% 
fetal bovine serum (JRH), and passaged at a 1:10 dilution every 3 days. 
 
II.9: Transfection 
 For transfection, HeLa S3, GM16147, VA13, and AG11395 were seeded at 
between 500,000 and 1,000,000 cells/per well of a 6 well dish 24hr before 
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transfection. Transfections followed this general format for 6 well dish: 
Lipofectamine2000 (10μL per well for HeLa S3 and GM16147, 5μL per well for 
AG11395 and VA13) was diluted into 240μL of OptiMEM and incubated for 5 min 
at room temperature. DNA (4μg for HeLa S3 and GM16147, 2μg for AG11395 and 
VA13) was diluted with OptiMEM to a final volume of 250μL. After the 5 minute 
lipofectamine incubation, the DNA and lipofectamine were mixed and incubated for 
an additional 20min before addition directly to each well of a 6 well dish, such that 
500μL total lipofectamine:DNA mix was added per well. Media was changed 24hr 
after transfection, and when necessary antibiotics were added at this time (3.3μg/mL 
Puromycin (Sigma) or 250μg/mL Hygromycin (Gibco)). 
 
II.10: Cloning TebDB and constructing Venus-TebDB fusion cDNA 
 The cDNA encoding amino acids 32-227 of the S. pombe ORF 
SPAC13G7.10 was obtained by PCR amplification with the forward primer BLoli 
1070 
5’TATGGATCCCCAAAGAAGAAGCGTAAGGTTGAAATGTCTAAAAGGGAG
GTAGCTCAAGATGTTCCAGG3’ containing a BamHI site for directional cloning,  
and reverse primer BLoli 1071 
5’TATGCGGCCGCCTATAGTTGTAGAACTATCGTTCGGGGTCGTAGC3’ with 
a NotI site, using S. pombe cDNA prepared from reverse-transcription of S. pombe 
total RNA with an oligo dT(12-18) primer performed and generously provided by K. 
 55
Trujillo. BLoli 1070 contains the cDNA encoding the amino acids for the nuclear 
localization sequence from SV40 large T antigen (PKKKRKVE), which facilitates 
import of proteins containing this sequence to the nucleus in mammalian systems. 
This PCR product was then cloned into pCR4-blunt for subcloning and sequencing. 
After successful sequencing of miniprep DNA, this product was then digested and 
ligated with T4 DNA ligase into pIRESneo2 that already contained the cDNA for the 
fluorescent protein Venus (purchased from the Stowers Institute Molecular Biology 
Facility), where Venus was inserted between NheI and BamHI sites. TebDB with the 
SV40 NLS was then inserted between BamHI and NotI sites in the pIRESneo2 
vector containing Venus, creating a Venus-TebDB fusion protein. For cloning 
Venus-TebDB into pIRESpuro2 and pIREShyg2, the Venus-TebDB fragment from 
Venus-TebDB-pIRESneo2 was excised with NheI and BstXI and cloned into these 
sites in the pIRESpuro2 and pIREShyg2 plasmids. 
 
II.11: Cloning Rap1-TebDB fusion proteins 
Human RAP1 in pGEX-4T was a gift from Z. Songyang. A cDNA encoding 
TebDB (amino acids 32-227 of Teb1, SpX, SPAC13G7.10) was cloned from cDNA 
generously provided by K. Trujillo. TebDB was inserted into pGEX-4T in frame 
with an N-terminal GST tag and thrombin cleavage site using BamHI and NotI sites, 
creating pJSCTeb. To create a GST-TebDB-RAP1 fusion protein (pJSC3), TebDB 
with flanking AscI sites was obtained by PCR with primers BLoli 1173 5’ 
TATGGCGCGCCATCTAAAAGGGAGGTAGCTCAAGATGTTC 3’ and BLoli 
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1174 5’TATGGCGCGCCTGTAGAACTATCGTTCGGGGTCGTAGCATC3’. This 
fragment was inserted into the AscI site between the thrombin cleavage site and 
RAP1 in RAP1-pGEX-4T. GST-tagged proteins were expressed in E. coli and bound 
to glutathione-coupled beads in batch. After elution with glutathione, thrombin 
(Amersham) cleavage was performed on GST-TebDB-RAP1 containing eluates. 
TebDB-RAP1 and GST-TebDB were further purified by mono Q ion-exchange 
chromatography. Protein concentrations were determined by Bradford assay 
(BioRad). 
To clone an hRAP1-Venus-TebDB fusion protein, the cDNA for RAP1 was 
PCR amplified with BLoli 1072 
5’TATGCTAGCATGGCGGAGGCGATGGATTTGGGCAAAG3’ containing an 
NheI site, and BLoli 1080 5’GTGTTTTTCTTTCGAAATTCAATCCTCCGAG3’, 
and cloned into pIRESneo2 using NheI and StuI sites. TebDB with the SV40 NLS 
was inserted in between the BamHI and NotI sites was obtained by PCR using the 
BLoli 1070 and BLoli 1071 and cloned into pIRESneo2 as indicated previously. 
Venus was then inserted between the HpaI and BamHI sites creating a Rap1-Venus-
TebDB fusion protein. The cDNA for this fusion protein was then cloned from 
pIRESneo2 into pIREShyg2 using NheI and BstXI. RAP1ΔCT with an N-terminal 
FLAG tag was purchased from Addgene (plasmid 13252)[66] and cloned into 





II.12: Cloning TRF2ΔBΔM and TRF2ΔB 
 TRF2ΔBΔM, which is a TRF2 fragment that lacks a.a. 1-43  and 446-499, 
was created from a PCR using BLoli 1008A  
5’GAGGCACGGCTGGAAGAGGCAGTC3’ and BLoli 1009 
5’TTGAGCGGCCGCTCACTTTTTTGTTATATTGGTTGTAC3’ with a TRF2 
cDNA-containing plasmid from Addgene (plasmid 12299)[48]. The PCR product 
was then cloned into pIND-V5 (Invitrogen), which contained an N-terminal FLAG 
tag, using EcoRV and NotI sites. TRF2ΔBΔM was then excised from this vector 
using NheI and NotI, and cloned into pIRESpuro2. TRF2ΔB was cloned in the same 
manner, except that BLoli 1010 
5’TTGAGCGGCCGCTCAGTTCATGCCAAGTCTTTTCATG3’ was used in place 
of BLoli 1009 so that the last 53 amino acids of TRF2 would be retained in the PCR 
product. 
 
II.13: Cloning mCherry-TRF1 and Venus-TRF1 fusions 
A plasmid containing TRF1 in pBluescript SK +/- (Addgene plasmid 
12303)[37] was used to clone TRF1 as a C-terminal fusion with mCherry into 
pIREShyg2. TRF1 with EcoRI and BamHI sites engineered by PCR using BLoli 
1083 5’TGGGAATTCATGGCGGAGGATGTTTCCTCAG3’ and BLoli 1084 
5’TGGGGATCCTCAGTCTTCGCTGTCTGAGGAAATC3’ was inserted into 
pIRESbleo using EcoRI and BamHI sites. An mCherry PCR product was inserted 
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upstream in between NotI and EcoRI sites following PCR with BLoli 1081 
5’TGGGCGGCCGCAATATGGTGAGCAAGGGCGAGGAGGATAAC3’ and 
BLoli 1082 5’TGGGAATTCCTTGTACAGCTCGTCCATGCCGCCGGTG3’ 
using mCherry cDNA obtained from the Stowers Institute Molecular Biology 
facility. The mCherry-TRF1 fusion was then cloned from pIRESbleo into 
pIREShyg2 using EcoRV and BamHI sites in pIRESbleo, and StuI and BamHI sites 
in pIREShyg2. For creation of pIRESbleo with a Venus-TRF1 fusion, mCherry was 
excised with EcoRV and EcoRI, and Venus was excised from RAP1-Venus-TebDB 
with HpaI and EcoRI and cloned into the gap created by removal of mCherry. 
Venus-TRF1 was then amplified by PCR with BLoli 1450 
5’TAAGCTAGCACCATGGTGAGCAAGGGCGAGGAGCTGTTC3’ and BLoli 
1451 5’AGTGGATCCTCAGTCTTCGCTGTCTGAG3’ that contained NheI and 
BamHI sites, respectively, and these sites were then used to clone Venus-TRF1 into 
pIREShyg2. 
 
II.14: Electrophoretic Mobility Shift Assays (EMSAs) 
DNA substrates were generated by annealing complementary oligo 
nucleotides. The G-rich strand for the telomeric substrate is 
5’ACGTGGTCAAAGTCTGGAAC(TTAGGG)10-3’, and 
5'ACGTGGTCAAAGTCTGGAAC(TGAGTG)10-3' for the scrambled substrate. The 
G-rich DNA oligonucleotides were labeled with [γ-32P]ATP using polynucleotide 
kinase and annealed with a 1.5 fold excess of the unlabelled complementary oligo. 
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The annealed products were purified over G-25 sepharose columns, and used for 
EMSA reactions at 0.4 nM.  Substrates were incubated with recombinant GST-
TebDB or TebDB-RAP1 at 225:1, 450:1, 900:1, and 1800:1 molar ratios of protein-
to-substrate in EMSA buffer (50mM TEA, pH7.5; 40mM KCl, 0.5mM DTT; 100 
μg/mL BSA) at room temperature for 10 minutes. DNA and DNA-protein complexes 
were resolved by electrophoresis on 6% polyacrylamide gels in 0.5X TBE buffer at 
200V for 5 minutes followed by 90 minutes at 90 V. The gels were dried and 
subjected to PhosphorImager analysis. Apparent dissociation constants Kd[app] were 
calculated from electrophoretic mobility shift assays as described above except that 
the DNA substrate was used at a final concentration of 0.09 nM. (Protein 
concentrations ranged in two-fold steps from 2.25nM to 36nM for GST-TebDB and 
in two-fold steps from 4.5nM to 72nM for TebDB-Rap1 for Kd.)  
 
II.15: In Vitro Non-Homologous End Joining Assays 
10μl reactions were carried out as follows: 6μl of deionized water was added 
to a 0.65mL microcentrifuge tube, and 1μl of NHEJ extract (prepared as described in 
[132]) and 2ul of 5X End-Joining Buffer (250mM TEA/OAc, pH 8.5, 300mM 
KOAc, 2.5mM Mg(OAc)2, 5mM ATP, 5mM DTT, 0.5mg/mL BSA) were then 
added to the tube. After incubation for 5 minutes at 370C, 1μl of DNA was then 
added, and the reaction was incubated at 370C for 1hr. The reaction was then stopped 
by addition of 2μl Stop Buffer (100mM Tris-HCl, pH7.5, 200mM EDTA, 10mg/mL 
proteinase K, 2.5% SDS) followed by a 15 min incubation at 420C. Products were 
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electrophoresed on 0.6% TBE gels and analysed using standard autoradiography 
methods. 
 
II.16: Cell culture and transfection 
HeLa S3 cells (ATCC) were grown in media containing DMEM 
supplemented with 2mM GlutaMAX (Invitrogen), 0.1mM non-essential amino acids 
(Invitrogen), and 10% fetal bovine serum (JRH). For transfection of cells for 
immunofluorescence, metaphase-spread FISH, or Western Blotting as performed in 
Chapter Three, cells were seeded at 5x105 cells per well in a 6 well dish and 
transfected with 4μg DNA using Lipofectamine 2000. After 4hr, cells were reseeded 
into two wells of a 6 well dish. 24hr after transfection, antibiotic selection was 
performed using media containing 3.3μg/mL puromycin (Sigma Aldrich), and 
250μg/mL Hygromycin B (Invitrogen). Dual antibiotic selection was employed to 
ensure that all cells analyzed by immunofluorescence, metaphase spread-TeloFISH, 
and Western blotting expressed the relevant proteins, thereby negating any effects 
due to differences in transfection efficiency. The effectiveness of antibiotic selection 
was assayed by quantifying the percentage of cells expressing either Venus-TebDB 
or Rap1ΔCT-Venus-TebDB 3 days after transfection. Fluorescence microscopy with 






Cells were seeded onto 22x22mm glass coverslips 4hr post transfection. After 
48hr of selection in media containing puromycin (3.3μg/mL) and hygromycin 
(250μg/mL), cells were washed once with PBS, and incubated with Triton extraction 
buffer  (300mM Sucrose, 20mM HEPES pH 7.9, 50mM NaCl, 3mM MgCl2, and 
0.5% Triton X-100) at 4oC for 2min. Cells were then washed twice with PBS, and 
fixed with 3% paraformaldehhyde and 2% sucrose in PBS for 10min. After fixation, 
cells were washed with PBS and repermeabilized with Triton extraction buffer for 
10min. Cells were then washed twice for 5 min with PBS, and blocking was 
performed for 45min in PBS containing 1% BSA. The TRF2 monoclonal antibody 
4A794 (Cat# 05-521, Millipore) and RAP1 polyclonal antibody (Cat# A300-306A, 
Bethyl Labs) were diluted 1:1000 in PBS with 1%BSA. Coverslips were incubated 
with primary antibodies for 2 hours followed by three 5 min washes in PBS with 1% 
BSA. Coverslips were then incubated with goat anti-mouse antibodies labeled with 
AlexaFluor 594 and goat anti-rabbit antibodies labeled with AlexaFluor 488 diluted 
1:1000 in PBS + 1% BSA for 1hr. Coverslips were washed twice in PBS with 1% 
BSA, stained with DAPI (200ng/mL) for 5 min, and mounted on slides with 
Fluoromount G mounting media. Microscopy was performed using an AxioPlan 
microscope with a 100X, 1.4 NA Plan-APOCHROMAT objective (Zeiss) and 
AxioVision software.   
 
II.18: Metaphase Spread preparation and Telomere-FISH 
 62
 Cells growing in media containing puromycin (3.3μg/mL) and hygromycin 
(250μg/mL) were treated with colcemid (0.1μg/mL) for 4hr and harvested by trypsin 
treatment 72hours after transfection. After hypotonic swelling in 10mL of 0.075M 
KCl at 37 oC for 7 min, cells were pelleted by centrifugation at 1000rpm for 
5minutes at room temperature in a Beckman Allegra 6R centrifuge. Next, the cell 
pellet was resuspended in 10mL 3:1 MeOH:CH3COOH, and cells were fixed in this 
solution for 10min. Cells were respun at 1000rpm for 5min at 4oC, and resuspended 
in 10mL of  3:1 MeOH:CH3COOH. This process was repeated an additional two 
times. Cells were dropped onto coverslips from a height of ~12 inches, washed once 
with 2mL of 3:1 MeOH:CH3COOH, and heated to 75 oC for 1min. After drying 
coverslips for 1hr at room temperature, individual coverslips were placed into wells 
of a 6 well dish and incubated in 3mL PBS for 10min to rehydrate the sample, and 
were then incubated at 37 oC for 30min in 3mL PBS with 0.5mg/mL RNAse A. 
Coverslips were then washed twice and fixed with 3mL of 4% paraformaldehyde in 
PBS for 10min. Fixative was then removed, and cells were washed twice with PBS-
A before addition of freshly dissolved and filtered Pepsin (Sigma) at a final 
concentration of 1mg/mL in pH2.0 ddH20. Pepsin treatment proceeded for 10min at 
37oC, followed by washing and re-fixing as was performed after RNAse A treatment. 
After the last PBS wash, cells were dehydrated in a 70%, 90%, 100% ethanol 
dehydration series (incubate in alcohol for 5 minutes per step), and allowed to dry for 
30-60min.  
 63
Hybridization of the sample was performed with 7.5μL of hybridization 
buffer (70% formamide, 0.25% blocking reagent (NEN Life Sciences, now 
PerkinElmer), 10mM Tris pH 7.0-7.5, 4.1 mM Na2HPO4, 0.45 mM citric acid, 1mM 
MgCl2, 100nM BLoli 1517 (Alexa 546-labeled 
5’CCCT+AA+CC+CT+AA+CC+CT+AA3’, where + is a locked nucleic acid) or 
100nM BLoli 1265 (Alexa 488-labeled 5’TTAGGGTTAGGGTTAGGG3’ with 
locked nucleic acids) being added to a large microscope slide, and the dried coverslip 
containing the sample was then gently lowered onto the droplet of probe. The sample 
was heated at 85oC for 3min, and then incubated for 80min at room temperature. The 
sample was then removed from the coverslip under PBS heated to 65oC, and was 
washed twice for 15min with 3mL of wash buffer (70% formamide, 10mM Tris, 
0.1% BSA, pH=7.0-7.5), followed by three more washes with 3mL of buffer 
containing (0.1 M Tris, 0.15 M NaCl, 0.08% Tween 20, pH=7.0-7.5). The sample 
was then stained with DAPI (2μg/mL) for 5min before mounting with Fluoromount 
G. 
Samples were imaged on an AxioPlan microscope with a 100X, 1.4 NA Plan-
APOCHROMAT objective (Zeiss) and AxioVision software. Quantification of 
telomere fusions was performed on blinded samples to remove experimenter bias. A 
chi-square test for independence was applied to the incidence of telomere fusions 
observed by metaphase spread analysis. Expected values were calculated based on 
the percentage of fused telomeres in cells expressing only TRF2ΔBΔM. Analyses 








Telomeres, the nucleo-protein structures found at the ends of linear 
chromosomes, promote genome stability by distinguishing chromosome termini from 
DNA double-strand breaks (DSBs). Cells possess two principal pathways for DSB 
repair, homologous recombination and non-homologous end joining (NHEJ). Several 
studies have implicated TRF2 in the protection of telomeres from NHEJ, but the 
underlying mechanism remains poorly understood.  Here, we show that TRF2 
promotes NHEJ inhibition by recruiting human RAP1 to telomeres.  Heterologous 
targeting of hRAP1 to telomeric DNA was sufficient to bypass the need for TRF2 in 
protecting telomeric DNA from NHEJ in vitro. Furthermore, recruitment of hRAP1 
to telomeres in cells alleviated the uncapping defect caused by the loss of 
TRF2/hRAP1 from chromosome ends upon expression of dominant negative TRF2. 
These results provide the first evidence that hRAP1 inhibits NHEJ at mammalian 
telomeres and identify hRAP1 as a mediator of genome stability in human cells.  
 
III.2: Introduction 
The prescient work of Barbara McClintock in the 1940s demonstrated that an 
essential function of telomeres is to prevent fusion of chromosome ends to de novo 
DNA breaks [19].  In order to fulfil this role, telomeres must locally inhibit the DNA 
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damage response; a feat that involves TRF2 and POT1 repressing DNA damage 
signalling through the ATM and ATR kinases [58].  Telomere dysfunction can result 
from a variety of events including structural changes at telomeres, loss of a telomere 
binding protein, or the gradual shortening of the telomeric repeat tract.  Proteins that 
specifically bind to telomeric repeats play a critical role in chromosome end 
protection, and their deletion results in telomere fusions in a broad range of 
species[24, 34, 73, 133, 134].  Early models of telomere protection predicted that 
telomere binding proteins outcompete the non-sequence specific binding of DNA 
repair factors near chromosome ends.  However, it has become apparent that key 
factors involved in DNA DSB repair are present at chromosome termini without 
triggering end-to-end fusions[135, 136]. The molecular mechanism underlying this 
phenomenon has remained elusive, but may relate to the t-loop, a structure in which 
the 3′ overhang of the telomere loops back and invades internal telomeric repeats on 
the same chromosome arm[76]. Such structures have been visualized by electron 
microscopy in DNA samples from a variety of species[77, 78, 82, 137]. 
A number of proteins have been identified that specifically localize to 
mammalian telomeres, including three factors that directly bind telomeric DNA:, 
POT1, TRF1, and TRF2, and three associated proteins TIN2, RAP1 and TPP1[138]. 
A truncated version of TRF2 (TRF2ΔBΔM) acts as a dominant negative mutant by 
forming heterodimers with the endogenous protein that are unable to bind to 
DNA[53]. Cells expressing TRF2ΔBΔM show reduced TRF2 at telomeres and 
chromosome ends are subject to NHEJ[25]. A requirement for TRF2 in chromosome 
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capping is further supported by the dramatic telomere fusion phenotype observed in 
mouse embryonic fibroblasts following deletion of TRF2[133].  
Using an in vitro assay for telomere capping we have previously shown that 
both hRAP1 and TRF2 are required to protect telomeric DNA ends from NHEJ[23].  
By targeting hRAP1 to telomeric DNA in the absence of TRF2 we now demonstrate 
that protection from NHEJ can be mediated by hRAP1 alone.  Our results suggest 
that hRAP1 provides the functional interaction that blocks NHEJ at telomeres with 
TRF2 serving to recruit hRAP1 to chromosome ends.  Consistent with these 
biochemical studies, targeting hRAP1 to telomeres in human cells independent of 
TRF2 provides efficient protection from the effects of TRF2ΔBΔM. 
 
III.3 Results 
III.3a RAP1 inhibits NHEJ in vitro 
In an attempt to define the specific functions of hRAP1 and TRF2 in 
protecting telomeric DNA ends from NHEJ we sought to bestow hRAP1 with the 
ability to bind vertebrate telomeric DNA independently of TRF2.  In this context, we 
examined the DNA binding domain of the S. pombe Teb1protein (also known as 
SpX). Teb1 was initially identified through computational approaches as a possible 
telomere binding protein[139], but biochemical experiments failed to demonstrate 
high affinity binding to fission yeast telomeric repeats and no function in telomere 
maintenance has been reported[140, 141]. Instead, Teb1 preferentially binds 
TTAGGG repeats and may function as a transcription factor for numerous S. pombe 
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genes containing this sequence motif in their promoters [141]. As TTAGGG 
corresponds to the vertebrate telomeric repeat we were intrigued by the possibility of 
utilizing Teb1 to target proteins of interest to human telomeres.  
To further characterize the Teb1 DNA binding domain (from hereon referred 
to as TebDB), we expressed and purified a 195 amino acid fragment of Teb1 fused to 
glutathione-S-transferase (GST).  TebDB showed robust and specific binding to 
vertebrate telomeric repeats (Figure 3.1a) with an apparent binding constant of 25 
nM. The reported Kd for TRF2 binding to telomeric DNA is 180 nM[52], suggesting 
that TebDB has similar affinity for human telomeric repeats to an endogenous 
telomere binding protein. Fusing hRAP1 to the N-terminus of TebDB did not 
diminish its affinity or specificity for binding to TTAGGG repeats (Figure 3.1b, 




Figure 3.1: RAP1-TebDB binds vertebrate telomeric DNA. (a) Electrophoretic 
mobility shift assay (EMSA) of double-stranded scrambled and telomeric DNA 
oligonucleotides incubated with indicated amounts of GST-TebDB. No protein was 
added in lanes 1 and 7. (b) EMSA of DNA substrates incubated with hRAP1-
TebDB. 
 
Having demonstrated that TebDB fusions to GST and hRAP1 bind human 
telomeric DNA in gel mobility shift assays, we tested the ability of these proteins to 
protect telomeric DNA from NHEJ in vitro. We have previously shown that 
telomeric DNA ends are protected from double-strand break repair activities when 
incubated with NHEJ-competent human lymphocyte extract [23].  After 
immunodepleting the extract of TRF2 and hRAP1 (Figure 3.2), end protection was 
lost but could be restored by adding back recombinant TRF2 and hRAP1, whereas 
addition of either protein alone was insufficient[23]. We now wanted to test whether 
TebDB-mediated recruitment of hRAP1 to telomeric DNA bypasses the need for 
TRF2. Addition of GST-TebDB to TRF2/hRAP1 immunodepleted extract had little 
effect on NHEJ at telomeric ends indicating that high affinity binding of this 
exogenous protein fails to recapitulate end protection (Figure 3.3a, lanes 3-6). 
Instead, a modest increase in end joining activity was observed at the lower 
concentrations of GST-TebDB (Figure 3.3a, lanes 3 and 4). In contrast, hRAP1-
TebDB inhibited end joining in a concentration dependent manner (lanes 7-10) with 
a five-fold reduction in end joining products being observed at a concentration where 
GST-TebDB had no effect (Figure 3.3a, compare lanes 5 and 9).  
To verify that the NHEJ-inhibiting activity of hRAP1-TebDB is due to 
recruitment of hRAP1 to telomeric DNA ends by TebDB, non-telomeric DNA ends 
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were also incubated with hRAP1/TRF2-immunodepleted extract. Though GST-
TebDB exhibited a very slight impact on end-joining (Figure 3.3b, lanes 2-4), 
hRAP1-TebDB had  no impact on NHEJ of non-telomeric ends (Figure 3.3b, lanes 5-
7). This result demonstrates that both the telomeric DNA binding ability of TebDB 
and the NHEJ-inhibiting activity of hRAP1 are responsible for telomeric end 
protection observed in this assay (Figure 3.3a). Because immunodepletion had 
removed most of TRF2  (Figure 3.2), these results suggest that TRF2 contributes to 
NHEJ inhibition at telomeres by recruiting hRAP1, which in turn blocks end joining. 
To test this model in vivo, we proceeded to evaluate ways of TRF2-independent 




Figure 3.2: Immunodepletion of hRAP1 results in loss of TRF2 from NHEJ-
competent extract. Mock (Rabbit IgG) or hRAP1-immunodepleted NHEJ-competent 
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extract was subjected to SDS-PAGE followed by immunoblotting analysis with a 
monoclonal TRF2 antibody (4A794) at 1:2000 and an HRP-conjugated goat anti-




Figure 3.3: Inhibition of end joining by hRAP1-TebDB specifically at telomeric 
DNA ends. (a) Linear plasmid DNA containing twelve 5’-TTAGGG-3’ repeats at 
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one end was incubated with GM00558 cell-free extract that was either mock 
depleted (lane 1), or immunodepleted (ID) of hRAP1 and TRF2 with anti-hRAP1 
(lanes 2-10). GST-TebDB (lanes 3-6) and hRAP1-TebDB (lanes 7-10) were added at 
the indicated concentrations prior to incubation with DNA substrates. As each DNA 
substrate contains one telomeric (head) and one non-telomeric (tail) end, the 
presence of tail-to-tail fusions serves as an internal control for the presence of NHEJ 
activity in the extract (lane 1).  End joining products were quantified by densitometry 
and were normalized to hRAP1-immunodepleted extract (lane 2).(b) Linear plasmid 
DNA containing twelve 5’-TGAGTG-3’ repeats at one end were incubated with 
GM00558 cell-free extract that was immunodepleted (ID) of hRAP1 and TRF2 with 
anti-hRAP1 (lanes 1-7). GST-TebDB (lanes 2-4) and hRAP1-TebDB (lanes 5-7) 
were added at the indicated concentrations prior to incubation with DNA substrates. 
End joining products were quantified by densitometry and were normalized to 
hRAP1-immunodepleted extract (lane 1). Gel was spliced to remove intervening 
lanes that were not pertinent to this experiment. 
 
III.b TebDB localizes  to human  telomeres in vivo 
Encouraged by the high affinity and specificity of TebDB for vertebrate 
telomeric DNA (Figure 3.1a), we examined the subcellular localization of TebDB 
fused to the GFP variant Venus.  To ensure efficient nuclear import, the nuclear 
localization signal from SV40 large T antigen was included in Venus-TebDB and all 
other TebDB-containing fusion constructs used in this study.  Fluorescence 
microscopic analysis of HeLa S3 cells expressing Venus-TebDB revealed punctate 
nuclear staining that largely colocalized with endogenous TRF2 (Figure 3.4a). 
However, a minor fraction of Venus-TebDB foci lacked a corresponding TRF2 
signal. This could reflect Venus-TebDB localization to non-telomeric sites in 
addition to telomeres. Alternatively, the fluorescent fusion protein may simply 
visualize telomeric loci more efficiently than the TRF2 antibody. To distinguish 
between these possibilities we generated a fusion of TRF1 to the fluorescent protein 
mCherry and examined the extent of co-localization with endogenous TRF2.  
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Consistent with fluorescent fusion proteins labeling telomeres more efficiently, all 
TRF2 foci colocalized with mCherry-TRF1, with a few additional mCherry-TRF1 
foci in places with weak or non-detectable TRF2 signal (Figure 3.4b). Finally, we 
co-expressed mCherry-TRF1 and Venus-TebDB and observed widespread co-
localization of the two proteins (Figure 3.4c).  We concluded that the TebDB is 
capable of mediating localization of fusion proteins to human telomeres in vivo.  
Figure 3.4: Telomeric localization of TebDB in human cells. (a) HeLa S3 cells 
transfected with Venus-TebDB (green) were stained with a mouse monoclonal 
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antibody for TRF2 followed by an AlexaFluor 594-conjugated secondary antibody 
(red). Nuclei were visualized by counterstaining with DAPI (blue). Cells were 
subjected to nucleoplasmic extraction so that only chromatin-associated proteins 
remain within nuclei. (b) Cells expressing mCherry-TRF1 (red) were stained with a 
mouse monoclonal antibody for TRF2 and AlexaFluor 488 secondary antibody 
(green). (c) Visualization of Venus-TebDB (green) and mCherry-TRF1 (red) in co-
transfected cells. All scale bars correspond to 10 μm. 
 
III.3c Expression of TRF2ΔBΔM results in preferential loss of hRAP1 from 
telomeres 
High-level expression of TRF2ΔBΔM is thought to drive endogenous TRF2 
into heterodimeric complexes that fail to bind telomeric DNA, thereby reducing the 
association of endogenous TRF2 with telomeres [53, 142].  Interestingly, several 
studies have indicated that telomeric TRF2 foci remain detectable in cells expressing 
TRF2ΔBΔM [53, 57, 143]. In addition, ChIP analysis from cells expressing 
Trf2ΔBΔM showed a 14-fold increase in 53BP1 levels at telomeres, while Trf2 was 
only reduced by 50% [57]. In light of the absence of haploinsufficiency in TRF2+/- 
heterozygous murine cells[58] and modest phenotypes observed in TRF2 knockdown 
experiments[144, 145] (our unpublished data), these observations suggest that 
TRF2ΔBΔM may mediate telomere uncapping by acting on multiple targets.  A 
likely candidate for such a target is hRAP1, which interacts with a region of TRF2 
present in the dominant negative fragment[65]. As TRF2ΔBΔM is expressed at much 
higher levels than endogenous TRF2, the majority of TRF2ΔBΔM is expected to 
form homodimers which lack the ability to bind telomeric DNA and have no effect 
on endogenous TRF2. However, endogenous hRAP1 may be sequestered by 
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TRF2ΔBΔM homodimers thus preventing its recruitment to telomeres.  To 
investigate the possibility that preferential loss of hRAP1 contributes to telomere 
fusions when TRF2ΔBΔM is expressed, we introduced TRF2ΔBΔM into HeLa S3 
cells and analyzed the localization of endogenous hRAP1 and TRF2.  A nucleoplasm 
extraction procedure[65] was used to ameliorate the high nucleoplasmic background 
associated with TRF2ΔBΔM expression when probing with an antibody against 
TRF2. While TRF2 and hRAP1 foci were prominent in cells transfected with empty 
vectors (Figure 3.5a), no telomeric hRAP1 was detected in TRF2ΔBΔM-expressing 
cells (Figure 3.5b). In contrast, and consistent with previous results[53, 65, 143], 
TRF2 foci were reduced but readily detectable in these cells (Figure 3.5b). We 
verified that the remaining TRF2 foci were telomeric in origin by co-expressing 
TRF2ΔBΔM and fluorescently-tagged TRF1 as a telomeric marker that is unaffected 
by TRF2ΔBΔM expression[53]. Following antibiotic selection to eliminate 
untransfected cells, telomeric TRF2 was observed in the majority of cells whereas 
hRAP1 was not detected (Figure 3.5c and d). Despite the presence of telomeric 
TRF2 in these cells, metaphase spreads confirmed widespread uncapping as 29.3% 
of telomeres had participated in fusions (see below).  In summary, these experiments 
revealed extensive telomere uncapping under conditions where TRF2 was detectable 
at telomeres while telomeric hRAP1 was not observed. We cannot rule out the 
possibility that differences in antibody affinity contribute to the apparent loss of 
hRAP1 but retention of telomeric TRF2. However, together with the in vitro work 
described above these results indicate that loss of hRAP1 may be primarily 
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responsible for telomere uncapping. A corollary to this hypothesis predicts that 
hRAP1 inhibits NHEJ at telomeres. 
 
Figure 3.5: Dominant negative TRF2 (TRF2ΔBΔM) preferentially removes hRAP1 
from telomeres. (a) Immunostaining of hRAP1 (AlexaFluor 488, green) and TRF2 
(AlexaFluor 594, red) in HeLa S3 cells transfected with and selected for the presence 
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of the vector controls. DNA was stained with DAPI (blue). (b) Visualization of 
TRF2 and hRAP1 as in (a) using cells expressing TRF2ΔBΔM. (c) Cells expressing 
TRF2ΔBΔM and Venus-TRF1 (green) were stained with an anti-TRF2 (AlexaFluor 
594, red) and DAPI (blue). (d) Cells as in (c) were stained with anti-hRAP1 
(AlexaFluor 594, red). All scale bars correspond to 10 μm. 
 
III.3d: TebDB neither uncaps nor protects human telomeres 
Telomeric localization of TebDB allowed us to target hRAP1 to chromosome 
ends independent of TRF2 and analyze whether such recruitment would ameliorate 
the effects of expressing TRF2ΔBΔM.  Prior to proceeding with this experiment we 
had to examine whether TebDB binding alone affected telomere function in vivo. To 
address this issue, we performed telomere-FISH on metaphase spreads prepared from 
cells transfected with empty vector, Venus-TebDB, or TRF2ΔBΔM. While 
chromosome structure was normal in cells harbouring the vector control (Figure 
3.6a), abundant chromosome fusions were observed in cells expressing TRF2ΔBΔM 
giving rise to long trains of fused chromosomes (Figure 3.6b). In contrast, no 
telomere fusions were observed in metaphases of cells expressing TebDB (Figure. 
3.6c). TebDB expression did result in an apparent increase in telomere length 
heterogeneity, suggesting some effect on telomere structure that may facilitate 
telomere recombination.  
Although TebDB alone was insufficient to protect telomeric DNA ends from 
NHEJ-mediated fusions in vitro (Figure 3.3), it was critical to test whether TebDB 
expression would partially or completely negate the effect of TRF2ΔBΔM in vivo. 
Analysis of metaphase spreads from cells co-expressing TebDB and TRF2ΔBΔM 
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revealed abundant telomere fusions (Figure 3.6d). In fact, co-expression with TebDB 
appeared to exacerbate the TRF2ΔBΔM phenotype.  This synergistic effect may be 
related to the increased telomere length heterogeneity caused by TebDB sensitizing 
telomeres to the loss of TRF2 and its interaction partners. However, as TebDB 
expression alone neither induced nor inhibited NHEJ-mediated telomere fusions, we 
proceeded to utilize this telomere binding domain to target hRAP1 to chromosome 
ends independent of TRF2. 
 
Figure 3.6: TebDB neither induces nor protects against NHEJ-dependent telomere 
fusions. Telomere-FISH was performed on metaphase spreads from cells transfected 
with and selected for vector control (a), TRF2ΔBΔM (b), Venus-TebDB (c), or 
Venus-TebDB and TRF2ΔBΔM (d). Telomeres were visualized with an AlexaFluor 
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543-labeled locked nucleic acid probe complementary to the G-rich strand (red). 
Chromosomes were counterstained with DAPI (blue). Representative chromosomes 
from the respective samples are shown. Some telomere:telomere fusions are 
highlighted with yellow arrows. 
 
III.3e: Telomeric hRAP1 counteracts uncapping by TRF2ΔBΔM 
To restore hRAP1 at telomeres following loss of TRF2, we fused Venus-
TebDB to a previously characterized hRAP1 fragment lacking the homodimerization 
and TRF2 interaction domains hRAP1ΔCT[65, 66]. The hRAP1ΔCT fragment was 
chosen as it cannot interact with either endogenous TRF2 or TRF2ΔBΔM and will 
therefore neither be recruited to telomeres by TRF2, nor will it interfere with the 
ability of TRF2ΔBΔM to remove endogenous hRAP1 and TRF2 from telomeres[69]. 
In contrast, a full length hRAP1-TebDB fusion efficiently recruited TRF2ΔBΔM to 
telomeres (Figure 3.7). As expected, hRAP1ΔCT-Venus-TebDB accumulated in foci 
that colocalized with TRF1 even when TRF2ΔBΔM was expressed (Figure 3.8a). We 
noted that co-expressing TebDB fusion proteins with TRF2ΔBΔM caused a further 
reduction in endogenous TRF2 foci, thereby providing us with a system in which 
TRF2 is not detected at telomeres but the hRAP1 fusion protein localises efficiently 




Figure 3.7: TRF2ΔBΔM can be recruited to telomeres by an hRAP1-Venus-TebDB 
fusion protein. (a). Cells transfected with FLAG-TRF2ΔBΔM and hRAP1-Venus-
TebDB were selected for expression of these proteins by treatment with puromycin 
and hygromycin for 48 h. Cells were then subjected to triton extraction, fixation, and 
immunostaining with a monoclonal anti-FLAG antibody (M2) at 1:1000, and a 
AlexaFluor 594-conjugated goat anti-mouse secondary antibody at 1:1000. Scale bar 
represents 10 μm. 
 
Next, we assayed the incidence of telomere fusions in metaphase spreads of 
cells co-expressing hRAP1ΔCT-Venus-TebDB and TRF2ΔBΔM. For comparison, 
telomere fusions were also scored in cells expressing only TRF2ΔBΔM and cells co-
expressing TRF2ΔBΔM and hRAP1ΔCT not fused to the TebDB domain.  The 
prevalence of telomere fusions observed in metaphase spreads of cells expressing 
hRAP1ΔCT and TRF2ΔBΔM (Figure 3.8c) contrasted sharply with cells co-
expressing hRAP1ΔCT-Venus-TebDB and TRF2ΔBΔM (Figure 3.8d).  Scoring of 
several thousand telomeres revealed that TRF2-independent recruitment of hRAP1 to 
telomeres caused a 10-fold reduction of end fusions when compared to cells 
expressing TRF2ΔBΔM alone (p<0.0001, Figure 3.9).  Importantly, expression of 
hRAP1ΔCT not fused to TebDB did not provide such protection, as the incidence of 
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telomere fusions was 7-fold higher in these cells (p<0.0001, Figure 3.9).  Immuno 
blotting confirmed that modulation of TRF2ΔBΔM expression was not the 
mechanism by which hRAP1ΔCT-V-TebDB protects telomeres as the dominant 
negative form of TRF2 was expressed at similar levels in all samples (Figure 3.10a). 
Furthermore, the hRAP1 fusion protein was expressed at similar levels to 
endogenous hRAP1, confirming that protection is not due to gross overexpression 
(Figure 3.10b). Taken together with the inability of Venus-TebDB to protect 
telomeres from NHEJ, our data strongly suggest that hRAP1 mediates protection of 
telomeres from NHEJ in human cells. 
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Figure 3.8: RAP1ΔCT-Venus-TebDB localizes to and protects telomeres in the 
absence of TRF2. (a) Colocalization of mCherry-TRF1 and hRAP1ΔCT-Venus-
TebDB at telomeres in cells expressing TRF2ΔBΔM. (b) Cells expressing 
TRF2ΔBΔM and hRAP1ΔCT-Venus-TebDB were stained with anti-TRF2 and 
AlexaFluor 594 conjugated secondary antibody (red). Nucleoplasmic extraction was 
employed to limit visualization to chromatin-associated TRF2. hRAP1ΔCT-Venus-
TebDB was visualized by virtue of Venus fluorescence. Scale bars correspond to 10 
μm. (c, d) Telomere-FISH performed on metaphase chromosomes transfected with 
and selected for expression of the indicated proteins. Telomeres were detected with 
an AlexaFluor 543-labeled locked nucleic acid probe that detects the G-rich strand 

































Figure 3.9: Quantification of telomere fusions in metaphase spreads of cells 
transfected with and selected for the indicated constructs. Telomere fusions were 





Figure 3.10: TRF2ΔBΔM is expressed at similar levels independent of which 
constructs are co-transfected. (a) Transfected cells were selected by treatment with 
puromycin and hygromycin and lysed 72 h post-transfection. Proteins were separated 
by SDS-PAGE and subjected to immunoblotting analysis using anti-TRF2 (4A794) 
at 1:2000 and HRP-conjugated goat anti-mouse at 1:5000 (Pierce). hRAP1-
containing constructs are expressed at similar levels (b). Cells from (a) were 
separated by SDS-PAGE and subjected to immunoblotting analysis using a 
polyclonal hRAP1 antibody at 1:1000 and HRP-conjugated goat anti-rabbit at 1:5000 
(Pierce). Endogenous hRap1 is indicated as a loading control for (b) and (a) since 




The isolation of a protein complex containing TRF1, TRF2, RAP1, TIN2, 
TPP1 and POT1[146, 147] has led to the proposal that all six telomeric proteins form 
a functional unit in chromosome capping. In reference to this putative role the six 
member complex has been named shelterin[148]. Efforts at elucidating shelterin 
function(s) have been hampered by both the varied phenotypes associated with loss 
of individual shelterin components as well as the identification of shelterin-
component specific subcomplexes [23, 58, 85, 149-152].  Delineating the roles of 
individual telomere proteins in telomere maintenance will shed light on both 
telomere subcomplex and shelterin functions. To this end, we have developed a 
system that targets proteins of interest to telomeres independently of their own 
capacity for DNA binding. The ability of the DNA binding domain from fission 
yeast Teb1 to bind vertebrate telomeric repeats with high specificity and affinity in 
vitro (Figure 3.1a), and to localize to mammalian telomeres in vivo (Figure 3.4a and 
b) provided us with a unique opportunity to investigate the functions of individual 
telomere-associated proteins in telomere protection. We found that NHEJ of 
telomeric termini was specifically inhibited upon TRF2-independent recruitment of 
hRAP1 to telomeric DNA in vitro (Figure 3.3), whereas TRF2 alone was insufficient 
to mediate protection. Extending these results in vivo, we demonstrate that 
heterologous targeting of hRAP1 to telomeres is sufficient to avert the uncapping 
phenotype associated with expression of dominant negative TRF2 (Figure 3.9).  The 
 85
convergence of biochemical and cell biological data presented here identify hRAP1 
as a critical mediator of telomere protection and genome stability in human cells.  
Uncovering roles for hRAP1 in telomere protection has proven challenging 
due in large part to the intricate relationship between hRAP1 and TRF2[138]. 
Previous studies have reported chromosome uncapping in response to removal of 
TRF2 from telomeres by various means including siRNA-mediated knockdown[144, 
145], expression of dominant negative forms of TRF2 [53, 131] and TIN2 [153]  and 
conditional knockout of TRF2 in mouse embryonic fibroblasts[133]. Furthermore, 
the stability of hRAP1 in cells depends on TRF2, as hRAP1 levels are drastically 
reduced in TRF2-/- MEFs[133]. Since removal of TRF2 from telomeres elicits the 
concomitant loss of hRAP1 [133], it has not been possible to distinguish the 
contributions of TRF2 and hRAP1 to telomere protection.  Importantly, the poorly 
understood end-joining phenotypes observed in TRF2 loss-of-function experiments 
are explained by the results presented here demonstrating that hRAP1 can protect 
telomeres from NHEJ, as concomitant loss of the NHEJ-inhibiting hRAP1 is 
anticipated to result in telomere deprotection.   
The mechanisms that telomeres employ to evade the DNA damage response 
are not clear, and subsequently the contribution of hRAP1 to telomere protection is 
not known[138]. Our experiments provide novel insight into hRAP1’s role in this 
process. Surprisingly, we find that hRAP1-dependent telomere protection is unlikely 
to operate through modulation of TRF2 DNA binding, as an hRAP1 fragment that is 
incapable of interacting with TRF2 efficiently protects telomeres from NHEJ (Figure 
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3.9). Our results also indicate that hRAP1 alone is sufficient to inhibit NHEJ (Figure 
3.2 and 3.9), showing that the interface between TRF2 and hRAP1 is not required for 
telomere protection. These results suggest a model whereby TRF2 protects telomeres 
by recruiting hRAP1 which in turn distinguishes telomeres from sites of de novo 
DNA damage (Figure 3.11). This model contrasts with current models of NHEJ 
inhibition at mammalian telomeres, which are largely based on the finding that a 
telomeric 3’ overhang can invade internal sequences on the same telomere thereby 
forming a t-loop that renders the end inaccessible to degradation or fusion [76]. 
Since TRF2 can promote t-loop formation in vitro[80], it has been suggested that 
chromosome fusions caused by the loss of TRF2 from telomeres are ultimately due 
to the dissociation or resolution of t-loops in the absence of TRF2.  However, this 
assertion remains to be tested. At least in vitro, t-loops are not required for NHEJ 
inhibition as 12 telomeric repeats are too short to form a t-loop but are sufficient to 
mediate protection of a DNA terminus from NHEJ[23].  Interestingly, similarly short 
but stable telomeres have been observed in vivo as well [87, 154]. An attractive 
explanation for this seeming discrepancy is that multiple pathways protect telomeric 
ends. For example, t-loops may protect long telomeres that are capable of forming 
such structures while very short telomeres that can not form t-loops are protected by 
hRAP1.  
The idea that multiple pathways protect telomeres in humans is supported by 
an emerging literature[23, 143, 152]. Recently, both phosphatase nuclear targeting 
subunit (PNUTS) and microcephalin (MCPH1) were shown to interact with a 
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domain in TRF2 that is separate from the hRAP1 interaction domain[143]. In 
addition, mutation of the PNUTS/MCPH1 binding site in DN-TRF2 reduced its 
ability to elicit a DNA damage signal at telomeres, suggesting that PNUTS and/or 
MCPH1 may also contribute to telomere protection. Taken together with our results 
showing that hRAP1 at telomeres can protect DNA ends from TRF2 loss, this 
combination strongly suggests that TRF2 mediates telomere protection through 
multiple distinct and possibly redundant pathways. Further analysis will be required 
to elucidate the links between hRAP1, PNUTS/MCPH1, t-loops and NHEJ-
inhibition at telomeres.  
Earlier work has shown that the other shelterin components continue to 
associate with telomeres following loss of TRF2/hRAP1[53, 57, 83, 84]. Our 
experiments do not exclude the possibility that TRF1, TIN2, TPP1 and/or POT1 may 
contribute to the hRAP1-dependent telomere capping reported here. However, a key 
role for hRAP1 is demonstrated by the observation that telomeric TIN2, TPP1 and 
POT1 are insufficient to prevent widespread telomere fusions, whereas recruitment 
of hRAP1 has a potent inhibitory effect on chromosome fusions. Previous studies 
suggest that any putative role for POT1 in inhibiting NHEJ at telomeres is minor 
since knockdown experiments show only modest increases in telomere fusions[155, 
156] and MEFs lacking Pot1a and b do not display the dramatic telomere fusion 
phenotype seen in cells lacking TRF2 [85, 157].  
Although hRAP1 was named based on limited domain and sequence 
similarity with the budding yeast repressor and activator protein (RAP1), the two 
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proteins have diverged substantially [65]. Unlike human RAP1 which has a single 
myb domain of unknown function, budding yeast RAP1 has tandem myb-like 
domains which mediate DNA binding critical for its functions in transcriptional 
regulation and telomere maintenance[158].  In S. cerevisiae recruitment of ScRIF2 
and ScSIR4 by the C-terminal domain of RAP1 is required for NHEJ inhibition at 
telomeres[68]. The C-terminal domain (CT) of hRAP1 mediates homodimerization 
and interaction with TRF2[65].  Consistent with divergent modes of inhibition, the 
CT of hRAP1 was not required for NHEJ inhibition in our experiments and 
homologues of yeast ScRIF2 and ScSIR4 appear to be absent from mammalian 
genomes. The divergence between ScRAP1 and hRAP1 may be explained by the 
realization that ScRAP1 binds telomeric DNA and inhibits NHEJ through multiple 
pathways, suggesting either that it may actually be a functional orthologue of TRF2 
rather than hRAP1, or that it has integrated TRF2 and hRAP1 functions into one 
protein.   
If ScRAP1 has indeed integrated the functions of TRF2 and hRAP1 into one 
module, then what functions of ScRAP1 and hRAP1 are conserved? Interestingly, a 
minor ScRAP1- dependent, but ScRIF2 and ScSIR4-independent NHEJ inhibition 
pathway has also been identified in yeast[68]. This pathway is not mediated by the 
conserved BRCT or CT domains in ScRAP1, but requires the central region of the 
protein. It is tempting to speculate that hRAP1 relies predominantly on this mode of 
NHEJ inhibition. Further supporting the idea of an evolutionarily conserved 
mechanism of NHEJ inhibition common to diverse RAP1 homologues is the 
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observation that loss of fission yeast SpRAP1 leads to telomere fusions[73], since no 
ScRIF2 or ScSIR4 homologues have been identified in this organism either. Several 
DNA repair factors including the Ku heterodimer, Mre11, Rad50, and PARP1 
copurify with hRAP1[69] raising the intriguing possibility that hRAP1 contains a 
domain that directly binds and prevents these proteins from executing DNA repair. 
Ku and DNA-PKcs associate with telomeres[159, 160] and at least in vitro hRAP1 
does not appear to inhibit the assembly of NHEJ factors at telomeric ends under 
conditions where it inhibits fusions (NSB, PB; unpublished data).   We expect that 
uncovering the physical and functional interactions between hRAP1 and the NHEJ 
machinery will now be critical to elucidating the mechanism by which chromosome 
ends are protected from unsolicited repair events. 
 




Replication Stress at Telomeres Results in “t-wrecks”, a New Type 




 Telomeres, the nucleoprotein structures that cap the ends of chromosomes, 
pose unique challenges to the DNA replication machinery. These challenges include 
telomeres’ repetitive nature, high guanine content, location at the terminus of 
chromosomes, and slough of factors that bind them with high affinity and specificity. 
Little is known about the strategies that the conventional DNA replication machinery 
employs to deal with these challenges. As much has been learned in biology through 
the study of mutant phenotypes, the identification of phenotypes associated with 
replication stress at telomeres may help to shed light on the process of normal 
telomere replication. To this end, we have identified the first example of dynamic 
telomere fusions caused by replication stress in metazoans. This novel type of fusion 
differs substantially from the previously reported NHEJ-dependent fusions 
associated with loss of TRF2 function, as they are NHEJ independent, contain large 
amounts of telomeric DNA and telomere binding proteins, and are not covalent. 
Most importantly, these fusions are induced by insults that cause replication stress at 
telomeres, and also appear to be dependent upon the RecQ helicase WRN for their 
formation. These characteristics indicate that telomere associations described here 
may be similar to the replication stress-induced “telomere entanglements” observed 
in fission yeast. The conservation of telomere entanglements between yeast and man 
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is illustrates the importance of the underappreciated role of semi-conservative DNA 
synthesis in telomere maintenance. 
 
IV.2: Introduction 
The highly repetitive nature of telomeres, their guanine-rich composition, the 
array of factors that specifically localize to them, their location at the termini of 
chromosomes, and the multiple conformations they can adopt makes these regions 
among the most difficult to replicate in eukaryotic genomes (Figure 1.6) [118, 161]. 
To counteract the difficulties associated with telomere replication, eukaryotic cells 
contain specialized machineries and mechanisms that facilitate initiation and 
progression of DNA synthesis through these challenging regions. However, most of 
the components of these machineries, as well as the mechanism of DNA synthesis 
through telomeres, remain elusive. Furthermore, what little is known about telomere 
replication comes primarily from budding yeast[162], whose mode of DNA 
replication differs substantially from other eukaryotes. A striking example of the 
difference between budding yeast DNA replication and DNA replication in other 
eukaryotes is the sequence-dependent initiation of replication at defined origins in 
budding yeast, which contrasts strongly with sequence-independent replication 
origins in other eukaryotes[163]. 
The origin recognition complex (ORC) is responsible for recognizing and 
licensing origins for DNA synthesis in all eukaryotes, however, requirements for 
ORC recruitment to mammalian origins independently of sequence context are still 
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not known [164]. Previous work has shown that the telomere binding protein TRF2 
binds the origin of replication in the Epstein Bar Virus (EBV) F1’ episome, which 
contains a triplex nonamer of TTAGGGTTA, and that this binding is essential for 
viral replication [165-167]. Related to this work, TRF2 has been shown to physically 
interact with ORC [55, 124], and it has also been shown that this interaction is 
necessary for the recruitment of ORC to the F1 origin of replication[167]. Finally, 
multiple groups have reported that TRF2 recruits ORC to mammalian telomeres, and 
that expression of a fragment of TRF2 that can not interact with ORC, TRF2ΔΒ, 
significantly reduces the amount of ORC at telomeres [55, 124]. The reduction in 
ORC at telomeres causes replication fork stalling through telomeric repeats and 
induces homologous recombination between sister telomeres presumably during 
repair of stalled telomeric forks [54, 55].  These results demonstrate that in addition 
to its role in telomere protection, TRF2 is a critical mediator of ORC recruitment and 
conventional DNA synthesis at telomeres. These results also identify TRF2ΔΒ as a 
potent inducer of replication stress at telomeres. 
 Here, we report a novel phenotype associated with replication stress at 
telomeres. In transformed cells expressing the telomere-specific inhibitor of 
replication TRF2ΔΒ, we observed chromatin bridges between sister nuclei in 
interphase. Characterization of these telomere associations indicates that they contain 
shelterin components and massive amounts of telomeric DNA. Surprisingly, these 
telomere associations do not require non-homologous end joining and are not 
covalent, explaining why they have been overlooked previously[54, 165]. These 
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telomere associations were observed in cell lines that maintain telomeres either 
through telomerase-mediated mechanisms or the alternative lengthening of telomeres 
pathway (ALT), suggesting that telomerase is not essential for their development. It 
also appears that the RecQ helicase WRN is essential for their formation, as 
TRF2ΔΒ-expressing fibroblasts derived from Werner syndrome patients do not 
display this phenotype. The finding that replication stress at telomeres appears to 
trigger dynamic telomere associations suggests that they may be similar to the 
“telomere entanglements” previously observed in fission yeast and that TRF2 and 
SpTaz1 may play similar roles in promoting telomere replication by the conventional 
DNA replication machinery [125, 128, 129]. The data presented here are also the 
first demonstration of replication stress at mammalian telomeres resulting in genome 




4.3a: TRF2ΔB induces chromatin bridges between sister nuclei that contain large 
amounts of telomeric DNA 
 During the course of studies on NHEJ-dependent telomere fusions induced 
by expression of TRF2ΔΒΔΜ, as a putatively negative control we expressed 
TRF2ΔΒ in HeLa S3 cells. TRF2ΔΒ was employed as a negative control because 
previous work showed that it caused telomere dysfunction without producing 
covalent telomere fusions [89]. Unexpectedly, expression of TRF2ΔΒ in HeLa S3 
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yielded numerous chromatin bridges between sister interphase nuclei (Figure 4.1a 
and c). This result appeared to be inconsistent with previous reports since expression 
of TRF2ΔΒ was shown to cause telomere recombination without yielding telomere 
fusions, and TRF2ΔΒ expression does not result in loss of shelterin components [89]. 
Quantification of the prevalence of chromatin bridges in cells expressing TRF2ΔΒ   
indicated that 74 out of 200 exhibited this phenotype, while 80 out of 207 cells 
displayed interphase bridges in cells expressing TRF2ΔBΔM. 
 Previous work has shown that TRF2 can localize to non-telomeric DNA 
breaks and may contribute to the repair process[50, 51, 168], suggesting that the 
chromatin bridges we observed may be due to dysfunctional DNA repair at non-
telomeric sites with subsequent induction of genomic instability. To address this 
issue, we investigated whether these chromatin bridges contained telomeric DNA. 
To accomplish this, HeLa S3 cells were transfected with either empty vector, 
TRF2ΔΒΔΜ, or TRF2ΔΒ, and subjected to fluorescence in situ hybridization (FISH) 
with a telomere-specific locked nucleic acid probe against the G-rich telomeric DNA 
strand. In this assay, we noted that telomere fusions in cells expressing TRF2ΔΒ 
invariably contained strikingly large amounts of telomeric DNA in all bridges 
observed in that sample, while TRF2ΔΒΔΜ induced bridges did not display this 
phenotype (Figure 4.1 a and b). Recent reports of telomeric RNA transcripts 
(TERRA) suggested that the telomeric signal observed in these bridges may result 
from an increase in telomere transcription [169]. However, since the FISH procedure 
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employed here contains an RNAse treatment step, it is unlikely that TERRA are 
primarily responsible for the telomeric signal seen in these bridges. 
Because there appeared to be more telomeric DNA in these bridges than is 
normally observed within the cell (Figure 4.1a), we hypothesized that these bridges 
may contain single-stranded DNA arising from uncontrolled DNA replication. To 
determine whether the DNA in the TRF2ΔΒ-induced chromatin bridges is double-
stranded, we probed these bridges with an LNA oligonucleotide against the C-rich 
telomeric strand (Figure 4.1c). As was observed with the probe against the G-strand, 
the C-strand probe specifically labeled chromatin bridges induced by TRF2ΔΒ, but 
not those induced by TRF2ΔΒΔΜ (Figure 4.1 c and d). This result indicates that the 
chromatin bridges induced by TRF2ΔΒ contain large amounts of double-stranded 
DNA. It is also possible that some single-stranded telomeric DNA is present in these 
bridges, however, potential differences in labeling efficiency of the C-and G-strand 
probes prevent us from addressing this issue. The massive accumulation of telomeric 
DNA in TRF2ΔΒ-induced bridges demonstrates that these bridges are cytologically 
distinct from the previously characterized NHEJ-dependent chromatin bridges 
caused by loss of TRF2 from telomeres [25, 53, 58, 130, 131, 133, 170].  
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Figure 4.1: TRF2ΔΒ induces chromatin bridges that contain large amounts of 
double-stranded telomeric DNA. (a,b) HeLa S3 expressing TRF2 fragments were 
stained with an AlexaFluor 543-labeled LNA probe detecting the G-rich telomeric 
DNA strand (green). DNA is stained with DAPI (red). (c,d) HeLa S3 expressing 
TRF2 fragments were stained an AlexaFluor488-labeled LNA probe detecting the C-
rich telomeric DNA strand (green). DNA is stained with DAPI (red). 
 
IV.3b: TRF2ΔB does not induce covalent telomere fusions 
 In an attempt to further characterize TRF2ΔΒ-induced telomere associations, 
we transfected cells with either empty vectors, TRF2ΔΒ, or TRF2ΔΒΔΜ and 
prepared metaphase spreads for telomere-FISH. In this assay, covalent non-sister 
telomere fusions give rise to chromosomes with telomere signals at their ends as well 
as internal telomeric DNA that represents the site of fusion. Fusions induced by loss 
 97
of TRF2 function such as those observed upon TRF2ΔΒΔΜ expression and 
expression of Cre in TRF2 -/flox MEFs display this phenotype [53, 58]. In contrast, 
it was previously reported that cells expressing TRF2ΔΒ did not display covalent 
telomere fusions [54], which is surprising in light of the chromatin bridge phenotype 
reported here (Figure 4.1 a and c). 
While cells containing empty vector had normal chromosome structure 
(Figure 4.2a), chromosomes from cells expressing TRF2ΔΒ displayed increased 
telomere length heterogeneity (TLH), telomeric DNA free ends (TFEs), and sister 
telomere fusions, all of which have been reported previously and are hallmarks of 
telomere recombination (Figure 4.2b) [54]. Critically, telomeres in these cells did not 
display covalent telomere:telomere fusions (Figure 4.2b), which is in agreement with 
previous work [54, 55]. To ensure that our metaphase spread protocol did not disrupt 
covalent telomere fusions, we analyzed telomere fusions in cells expressing 
TRF2ΔΒΔΜ. In accordance with published results, these cells had massive 
chromosome fusions with telomeres at the fusion points (Figure 4.2c). This data 
suggests that the version of TRF2ΔΒ expressed here acts in a similar manner to the 
versions of TRF2ΔΒ employed in previous reports and that TRF2ΔΒ induces non-
covalent telomere associations [56, 89, 165]. 
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Figure 4.2: Telomere FISH on metaphase spreads from HeLa S3 transfected with 
the indicated constructs. LNA probe detecting the G-rich telomeric DNA strand was 
labeled with AlexaFluor 543 (green) to visualize telomeres. DNA stained with DAPI 
(red). (a) HeLa S3 transfected with empty vector. (b) HeLa S3 transfected with 
TRF2ΔΒ. Telomere dysfunction including telomere free ends and sister chromatid 
fusions indicated by white arrows. (c) HeLa S3 transfected with TRF2ΔΒΔΜ. White 
arrows show telomere:telomere fusions. (d) HeLa S3 transfected with TebDB. White 
arrows show telomere free ends and sister telomere recombination events.  
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The dramatic increase in TLH, sister telomere recombination, and TFEs 
induced by TRF2ΔΒ is similar to the phenotype displayed by human cells 
heterologously expressing the DNA binding domain from the fission yeast protein 
SpTeb1. This protein was initially identified in a bioinformatics search for fission 
yeast homologues of TRF1/2 based on its highly conserved Myb domain [139]. 
Though SpTeb1 does not function in fission yeast telomere maintenance, we and 
others have previously shown that  a fragment of SpTeb1 carrying the DNA binding 
domain, TebDB, binds the vertebrate telomeric repeat with high affinity and 
specificity, and that it can localize to mammalian telomeres (Figures 3.1, 3.4). 
Furthermore, TebDB expression in HeLa S3 leads to increased TLH, TFEs, and 
sister telomere recombination (Figure 4.2d). Suspecting that TebDB may induce 
telomere fusions that are similar to those induced by TRF2ΔΒ, we expressed a 
Venus-TebDB fusion protein in HeLa S3 cells and performed telomere-FISH. These 
cells displayed a dramatic accumulation of double-stranded telomeric DNA within 
chromatin bridges (Figure 4.3 a and b), appearing identical to those observed upon 
expression of TRF2ΔΒ. This result clearly demonstrates that Trf2ΔΒ and TebDB 
elicit similar telomere dysfunction resulting in non-covalent telomere associations. 
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Figure 4.3: TebDB induces non-covalent telomere associations. HeLa S3 expressing 
TebDB were stained with an LNA oligonucleotide probe detecting the C-rich strand 
(a, green), or G-rich strand (b, green). DNA was stained with DAPI (red). 
 
IV.3c: Double-stranded telomere binding proteins localize to TRF2ΔB-induced 
chromatin bridges 
The fusion of TebDB to the yellow fluorescent protein variant Venus also 
provided an opportunity to examine whether TebDB localized not only to telomeres, 
but also to chromatin bridges containing telomeric DNA. This experiment would 
further demonstrate that these bridges contain double-stranded telomeric DNA, since 
TebDB specifically binds the double-stranded TTAGGG sequence, and not its 
single-stranded counterpart[141]. Cells expressing Venus-TebDB exhibited 
numerous chromatin bridges between cells, and the Venus-TebDB fusion protein 
localized to these structures (Figure 4.4a). The finding that Venus-TebDB, a protein 
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that localizes to mammalian telomeres (Figure 3.4), also localized to chromatin 
bridges suggested that other telomere binding proteins, including TRF1 and TRF2, 
may localize to these structures. If so, these telomere association would be the first 
example of telomere dysfunction with an accumulation of telomere binding proteins 
at the site of fusion. This finding would also help to shed light on the mechanism by 
which these fusions arise, as it would appear unlikely that DNA damage signaling 
through the ATM kinase would be responsible for these fusions since the ATM 
inhibitor TRF2 would be present at the site of dysfunction[58, 59] . 
To investigate the localization of human telomere binding proteins at sites of 
telomere fusion, we stained HeLa S3 expressing TRF2ΔΒ and TRF2ΔΒΔΜ with an 
antibody against TRF2. TRF2ΔΒΔΜ mediated fusions are caused by loss of TRF2 
and associated factors from telomeres, leading to NHEJ dependent telomere fusions. 
As expected, TRF2ΔΒΔΜ removed TRF2 from telomeres, and the chromatin bridges 
between sister nuclei did not contain TRF2 (Figure 4.4c). In contrast, the TRF2 
antibody brightly labeled the telomere bridges induced by TRF2ΔΒ (Figure 4.4b). It 
is important to note that the TRF2 antibody used here can not distinguish 
endogenous TRF2 from TRF2ΔΒ, therefore the localization of endogenous TRF2 in 
these bridges is unknown. Since previous reports have demonstrated that TRF2ΔΒ 
does not displace and in fact robustly colocalizes with endogenous TRF2 [54], and 
that these bridges contain large amounts of double-stranded telomeric DNA (Figure 
4.1 a and c), it is likely that both TRF2 alleles reside in the chromatin bridges.  
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We also assayed TRF1 localization in cells expressing TRF2ΔΒM, TRF2ΔΒ, 
and Venus-TebDB. To do this, we used a mCherry-TRF1 fusion protein that we have 
previously shown colocalizes with endogenous TRF2 (Figure 3.4). mCherry-TRF1 
was co-transfected with either TRF2ΔΒΔM, TRF2ΔΒ, or Venus-TebDB, and cells 
were visualized 48hr after transfection. Figure 4.4 (a,d,e) clearly shows that bridges 
in cells expressing Venus-TebDB, TRF2ΔΒ, and TRF2ΔΒΔΜ are all labeled with 
mCherry-TRF1. Recent work demonstrating a role for TRF1 in the resolution of 
sister telomeres during mitosis provides an explanation for the localization of 
mCherry-TRF1 to bridges induced by Venus-TebDB, TRF2ΔΒ, and TRF2ΔΒΔΜ 
[43-45]. While the accumulation of double-stranded telomeric DNA in bridges 
induced by Venus-TebDB and TRF2ΔΒ is sufficient to explain mCherry-TRF1 
localization to these structures, it is possible that fused telomeres of dicentric 
chromosomes in cells expressing TRF2ΔΒΔΜ accumulate TRF1 since they can not 




Figure 4.4: TRF2 and mCherry-TRF1 localize to chromatin bridges induced by 
telomere dysfunction. (a) HeLa S3 expressing Venus-TebDB (green) and mCherry-
TRF1 (red). TRF2 staining (red) in cells expressing TRF2ΔΒ (b) or TRF2ΔΒΔΜ (c). 
DNA was visualized with DAPI (blue). (d) HeLa S3 expressing TRF2ΔΒ and 









IV.3d: TRF2ΔB can induce telomere associations in ALT cells 
 Transformed cell lines can maintain their telomeres by multiple mechanisms, 
including telomerase-mediated telomere extension and a homologous recombination-
based mechanism called alternative lengthening of telomeres (ALT) [110]. Because 
telomeres in ALT positive cells display increases in TLH, TFEs, and sister chromatid 
recombination events[54], we wondered whether ALT cells also display non-
covalent telomere fusions at a low frequency. In addition, it is also possible that ALT 
cell lines have developed mechanisms to counteract the formation of telomere 
entanglements, thus rendering them immune to the effects of TRF2ΔΒ or Venus-
TebDB expression. Moreover, since ALT cell lines do not express telomerase, the 
contribution of telomerase to these novel telomere associations can be addressed. To 
answer these questions, we transfected the ALT cell line VA-13 with either empty 
vector, TRF2ΔΒ, or Venus-TebDB, and performed telomere-FISH on these cells 
48hr after transfection. Although examination of 250 cells transfected with empty 
vectors did not yield telomeric-DNA containing-chromatin bridges (Figure 4.5a), 78 
out of 250 cells expressing TRF2ΔΒ displayed numerous telomere associations, and 
VA-13 expressing TebDB displayed these bridges as well (Figure 4.5 b and c). 
Despite rigorous attempts to identify telomere entanglements in ALT cells 
transfected with empty vector, none were observed. Thus, it appears that these 
entanglements do not arise spontaneously in ALT cells in spite of the TLH, TFEs, 
and sister telomere recombination events. However, it is clear that ALT cell lines do 
not contain a mechanism to prevent the formation of such entanglements, as 
 105
TRF2ΔΒ and Venus-TebDB elicited telomere entanglements in VA-13. It is also 
important to note that telomerase is not required for the formation of these structures, 
since VA-13 do not contain telomerase. Because telomeres are synthesized by only 
two means, telomerase and the conventional DNA replication machinery, DNA 




Figure 4.5: TRF2ΔΒ and TebDB induce chromatin bridges in ALT cells. (a,b,c) 
VA-13 were transfected with the indicated constructs and stained with an AlexaFluor 
543-labeled LNA probe that detects the G-rich strand of telomeric DNA (green). 
DNA was stained with DAPI (red). 
 
IV.3e: Telomere associations are NHEJ-independent 
 Non-homologous end joining is one pathway used by cells to repair DNA 
double strand breaks. The NHEJ machinery consists of the DNA end binding 
proteins Ku 70 and Ku86, the DNA-dependent protein kinase catalytic subunit DNA-
PKcs, DNA ligase IV, and its stimulatory factor XRCC4 [8]. All of these proteins are 
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required for NHEJ, as loss of any single component renders the conventional NHEJ 
machinery inactive. This pathway is primarily active in the G1-phase of the cell 
cycle, and is responsible for fusion of dysfunctional telomeres caused by loss of 
TRF2 and associated factors from chromosome ends, including TRF2ΔΒΔM-induced 
telomere fusions [14, 25]. Because this pathway was recently implicated in the 
covalent fusion of sister telomeres during G2 [45], we investigated whether covalent 
sister telomere fusion is responsible for the chromatin bridges observed upon 
expression of TRF2ΔΒ or Venus-TebDB. To this end, we expressed Venus-TebDB 
in the NHEJ-deficient Chinese hamster cell line GM16147, an XRCC4 null cell line 
that is devoid of NHEJ activity [171]. If chromatin bridges containing telomeric 
DNA are indeed found in this cell line, they are by definition NHEJ-independent. In 
GM16147 expressing Venus-TebDB and mCherry-TRF1, we observed chromatin 
bridges similar to those seen in HeLa S3 (Figure 4.6a and b). The presence of 
telomeric DNA in these bridges (Figure 4.6b) demonstrates that they are indeed 
identical to those observed in HeLa S3 upon expression of either TebDB or 
TRF2ΔΒ. In contrast, in GM16147 transfected with empty vector, no such structures 




Figure 4.6: Telomere associations induced by TebDB in an NHEJ-deficient cell line. 
(a) The NHEJ-deficient XRCC4 null cell line GM16147 was transfected with 
mCherry-TRF1 (red) and Venus-TebDB (green). DNA was visualized with DAPI 
(blue). (b) The same cells in (a) were subjected to telomere-FISH with an LNA probe 
that detects the G-rich strand of telomeric DNA (green). DNA was visualized with 
DAPI (red). 
 
IV.3f: WRN may be required for telomere association formation 
 The finding that NHEJ was not required for entanglement formation, coupled 
with data demonstrating that TRF2ΔΒ causes replication fork stalling at telomeres, 
suggests a model where compromised telomere replication leads to aberrant 
homologous recombination between both sister and non-sister telomeres. Previous 
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reports have shown that replication stress-induced telomere entanglements in fission 
yeast required the RecQ helicase SpRqh1 acting inappropriately at telomeres for 
their formation [128]. Interestingly, a recent report also showed that telomere 
recombination induced by TRF2ΔΒ is mediated by the SpRqh1 homologue WRN in 
humans [56]. WRN is a helicase best known for its role in the pathogenesis of 
Werner’s syndrome, a progeroid disorder [121]. This helicase/nuclease plays 
important but poorly understood roles in DNA repair particularly during S-phase, the 
phase during which telomere entanglements are thought to occur [125, 128]. Because 
the aberrant function of SpRqh1 at dysfunctional telomeres led to telomere 
entanglements in fission yeast, we hypothesized that fibroblasts from patients with 
Werner’s syndrome should actually be spared from telomere entanglements induced 
by TRF2ΔΒ and Venus-TebDB.  
To address the role of WRN in creating telomere entanglements, we used a 
transformed WRN fibroblast cell line (AG11395) that does not contain WRN activity 
due to the presence of a homozygous mutation in exon 9 (C>T) that creates a protein 
with a premature stop codon (Arg368Stop) [172]. The mRNA that encodes this 
truncated protein is expected to be degraded by the non-sense mediated decay 
machinery, and this cell line has been shown to be deficient in DNA mismatch repair 
[173]. After transfection with either TRF2ΔΒ, Venus-TebDB, or empty vector, cells 
were subjected to either telomere-FISH or fluorescence microscopy to observe 
telomere entanglements. In AG11395 expressing either TRF2ΔΒ or Venus-TebDB, 
no telomere entanglements were found in 250 cells examined, suggesting that 
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telomere entanglements require WRN for their formation (Figure 4.7 a and c). 
Because we did not have either WRN cDNA or an isogenic WRN-positive 
counterpart for AG11395, we employed VA-13 as a positive control because it 
possesses WRN activity but is also an SV40-transformed fibroblast cell line that 
maintains its telomeres by ALT, similar to AG11395. Analysis of 250 VA-13 cells 
expressing TRF2ΔΒ yielded 78 telomere fusions, demonstrating that VA-13 are 
susceptible to telomere entanglements (Figure 4.5 b and c and Figure 4.7b), 
suggesting that WRN deficiency in AG11395 is responsible for protection against 
telomere entanglement. It is important to note that the Venus-TebDB fusion protein 
seems to label not only the chromatin bridges between cells, but also labels filament-
like protrusions from these bridges that appear to arise from the mechanical stress 





Figure 4.7: WRN may be required for formation of chromatin bridges caused by 
TRF2ΔΒ and TebDB expression. (a) The WRN deficient ALT cell line AG11395 
was transfected with TRF2ΔΒ and stained with an LNA probe that detects the G-rich 
telomeric DNA strand (green). DNA was visualized with DAPI (red). (b) VA-13 
were transfected with Venus-TebDB (green). DNA was stained with DAPI (blue). 




An essential and overlooked aspect of telomere maintenance is the replication 
of telomeric DNA carried out by the conventional DNA replication machinery. 
Although the end-replication problem associated with lagging-strand synthesis has 
garnered much publicity due to its contributions to aging and cancer [101, 105, 106], 
little attention has been paid to the machinery that is responsible for synthesizing the 
lion’s share of telomeric DNA. Considering the inherent difficulties in replicating the 
G-rich strand and the fact that this process is essential for cellular proliferation, the 
lack of attention given to this topic is surprising. It is hoped that the identification of 
phenotypes caused by dysfunctional semi-conservative DNA replication at telomeres 
may lead to the identification of factors and mechanisms that cells employ to 
replicate this and other challenging DNA. 
In this work, we have shown that replication stress at mammalian telomeres 
can result in telomere entanglements. These entanglements contain telomeric DNA, 
TRF1, and TRF2, demonstrating that they are cytologically distinct from previously 
reported mammalian telomere fusions. Importantly, these entanglements are NHEJ-
independent and thus are not covalent, providing the first example of non-covalent 
telomere associations in metazoans. We also show that they can occur in ALT cell 
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lines, suggesting that they do not require telomerase for their formation. Finally, they 
appear to require the RecQ helicase WRN and possibly mismatch repair for their 
creation, as WRN deficient patient fibroblasts are immune to this phenotype. These 
results indicate that we have identified a novel type of mammalian telomere fusion 
that can occur in a wide variety of cell lines. Keeping with the tradition of naming 
telomere specific structures with “t-“, including “t-loops”, “t-stumps”, and “t-
complexes” [76, 154, 174], we have named this new class of telomere entanglements 
“t-wrecks”. 
How do t-wrecks form? Combining results presented here and elsewhere, the 
initial event in t-wreck formation is the stalling of replication forks within telomeric 
repeats [55, 125]. When a replication fork stalls in a telomere, repair by homologous 
recombination leads to either intra- or inter-telomeric recombination (Figure 4.8) 
[54]. These recombination events can then lead to t-circle and/or unresolved 
Holliday Junction formation [54, 56, 128, 174]. In the case of t-circle formation, 
these molecules can serve as templates for rolling circle replication, yielding large 
amounts of extrachromosomal telomeric DNA (Figure 4.1, 4.3, 4.5)[174, 175] 
(Figure 4.8). If inter-telomere recombination occurs, aberrant processing by 
SUMOylated RecQ helicases including SpRqh1 and WRN may create structures that 
can not be untangled by resolvases [128] which would lead to interchromosomal 
associations mediated by dynamic HJ-like structures (Figure 4.9). Since both t-circle 
and telomere-specific recombination intermediates depend on the activity of WRN 
[66, 128], either of these possibilities are consistent with our results. Furthermore, 
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since the HR pathway would be used in each of these cases, NHEJ would be 
dispensable for t-wreck formation.  
Recombination events alone do not explain the t-wreck phenotype, however. 
The formation of telomeric DNA-containing chromatin bridges, as observed in t-
wrecks (Figure 4.1, 4.3, 4.5), could be the result of homo or heterotypic 
protein:protein interactions between proteins that bind both t-circles and telomeres. 
Attractive candidates for these proteins include TRF1 and cohesins, both of which 
are involved in sister telomere segregation [43-45] and are consistent with the 
finding that TRF1 localizes to these bridges (Figure 4.4, 4.6). The segregation of 
centromeres to daughter nuclei during mitosis would lead to lagging t-circle/telomere 
structures that accumulate between sister nuclei, as observed in t-wrecks and 
telomere entanglements (Figure 4.9)[129]. This explanation is also intriguing 
because the protein:protein interactions at the heart of t-wrecks would be disrupted 
by the hypotonic swelling step in the metaphase spread preparation protocol [44], 
providing an explanation for the failure to visualize t-wrecks in metaphase spreads.  
Another explanation for the inability of t-wrecks to survive metaphase spread 
preparation is that they result from unresolved HJs between sister telomeres (Figure 
4.8). These structures would also “lag” between sister nuclei after mitosis, and the 
well-known requirement for salt during HJ formation[176] also explains the 
sensitivity to hypotonic swelling. It is also possible that both t-circles and inter-
telomere recombination work together to produce t-wrecks; further investigation of t-
wrecks will help to elucidate this issue. An interesting test of the potential 
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contribution of t-circles to t-wreck formation is to transfect circular plasmids 
containing several kilobases of telomeric DNA, and to assay t-wreck prevalence 48hr 
after transfection. The prediction is that circular plasmids containing telomeric DNA 
would be replicated by rolling circle replication, leading to accumulation of large 
amounts of telomeric DNA that become entangled during anaphase, yielding t-
wrecks and demonstrating a role for t-circles in t-wreck formation. 
The telomere entanglements identified here help to resolve a poorly 
understood issue in the telomere field. Previous work demonstrated that both cells 
expressing TRF2ΔΒ and ALT cells exhibited TLH, TFEs, SCEs, and spontaneous t-
circle formation, however, it was unclear why cells expressing TRF2ΔΒ died given 
that similar dysfunction in ALT cells did not lead to their demise[54]. It appears that 
TRF2ΔΒ elicits telomere dysfunction to such an extent that telomere entanglements 
ensue, while the low levels of spontaneous telomere dysfunction in ALT cells are not 
sufficient to cause entanglements.  
In addition, this report identifies TebDB as a new tool for both visualizing 
telomeres in species with TTAGGG-containing telomeric repeats, as well as 
inducing telomere dysfunction in cells undergoing DNA replication. The ability of 
TebDB to induce telomere dysfunction that contains the hallmarks of replication 
stress at telomeres suggests that TebDB causes telomere dysfunction by interfering 
with telomere replication. As TebDB binds telomeric DNA with extraordinarily high 
affinity (Kd=15nM) in vitro (Figure 3.1), it is unsurprising that the replication fork 
may halt when TebDB molecules are encountered. TebDB comes from a fission 
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yeast protein whose normal DNA binding regulation is unlikely to be recapitulated in 
mammalian cells. This situation is reminiscent of replication fork stalling induced by 
TRF1 and TRF2 in an in vitro system that recapitulates semi-conservative telomeric 
DNA replication [177].  It is possible that fission yeast contains a mechanism to 
regulate the binding of TebDB to S. pombe DNA such TebDB does not bind in S-
phase, while mammalian cells have no way to regulate heterologously expressed 
TebDB. Furthermore, it is interesting to speculate that both TRF1 and TRF2 bind 
telomeres in a regulated manner, such that their binding affinity for telomeric DNA 
is reduced in S-phase to allow replication fork progression[124, 177]. The binding of 
TRF2 to telomeres in S-phase may be affected by its interaction with ORC, such that 
ORC binding to TRF2 weakens TRF2’s affinity for DNA, allowing replication fork 
progression [124]. 
This work demonstrates that replication stress at mammalian telomeres 
results in t-wrecks, which are reminiscent of fission yeast telomere entanglements. 
The finding of t-wrecks in species ranging from fission yeast to hamster to human is 
a testament to the importance of conventional DNA synthesis in maintaining 
telomeres, and the deleterious consequences of replication stress at telomeres 
regardless of the telomeric repeat sequence (e.g. vertebrates are 5’ TTAGGG 3’ and 
fission yeast is 5’ G1–8TTACA0–1C0–1 3’). We have  identified both a novel 
phenotype associated with replication stress at mammalian telomeres, the presence of 
large amounts of telomeric DNA within chromatin bridges between sister nuclei in 
interphase, and a tool to induce this type of dysfunction in any vertebrate, TebDB. 
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The identification of this new phenotype and a tool for its induction will undoubtedly 
facilitate the discovery of other circumstances that lead to t-wreck formation, factors 
that involved in their development, including TRF2 and WRN, and their potential 
contributions to diseases such as Werner’s Syndrome. 
 
Figure 4.8: Consequences of inter-and intra-telomeric homologous recombination 
during the repair of stalled replication forks. Inter-telomere HR may lead to HR 
intermediates that are difficult to resolve, while intra-telomere HR can yield t-circles 
with subsequent induction of rolling-circle replication leading to accumulation of 
large amounts of telomeric DNA. Adapted with permission from the American 














Rolling circle  
replication 
Dynamic associations between t-circles 
and telomeres (HJs or Protein:Protein) 




























Figure 4.9. Model for t-wreck formation based on sister telomere recombination 















Conclusions and Future Directions 
 
 
V.1: Future directions for Chapter 3 
 
 Research into cell biology and cytogenetics has been one of the most fruitful 
areas of science in the past 75 years. Within this field, arguably the most progress 
has been made in the subdiscipline of DNA damage and repair. Since initial work by 
McClintock and Muller, much knowledge has been gained about the types of damage 
DNA encounters and the complicated machineries that cells contain for repair. 
Although research in this area of biology has yielded key concepts and principals of 
DNA repair, little progress has been made in understanding how naturally occurring 
chromosome termini of eukaryotic genomes escapes recognition by the DNA repair 
machinery. The inability to dissect the intricate relationship between DNA repair and 
telomere maintenance is directly related to both the complexity of the DNA repair 
machineries and the intractable nature of highly repetitive DNA elements. Due to the 
complexity of this relationship, we sought to establish a more feasible paradigm for 
interrogating connections between DNA repair and telomere maintenance: how are 
telomeres protected from illegitimate processing by the NHEJ machinery? 
The development of a novel system that allows for the recruitment of proteins 
to telomeres independently of their own capacity for DNA binding provides a new 
tool for investigation of the relationship between telomeres and DNA repair. We 
have shown that the DNA binding domain from the S. pombe protein Teb1, TebDB, 
binds vertebrate telomeric DNA in vitro and localizes to mammalian telomeres in 
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vivo. We also showed that TebDB can efficiently recruit proteins of interest to 
telomeres. Finally and most importantly, we showed that fusion of the TRF2-
interacting factor hRAP1 to TebDB protects telomeres from the end-joining 
phenotype associated with loss of hRAP1/TRF2 from telomeres both in vitro and in 
vivo. These results identify hRAP1 as a critical mediator of telomere protection and 
genome stability in humans, and indicate that despite highly diverged functions, 
RAP1 homologues have conserved roles in telomere protection. Though both the 
development of a new system to tease apart the contribution of telomere binding 
proteins to telomere protection and the identification of a protective function for 
hRAP1 are important contributions to the telomere field, I believe the most important 
contribution of the research presented in Chapter Three are the new questions raised 
by these results.  
The first and most pressing question put forth by the data reported in Chapter 
Three pertains to the mechanism by which hRAP1 protects telomeres. Loss of 
function experiments with hRAP1 are an obvious place to start and would help to 
shed light on this issue, however, mammalian RAP1 has not yet yielded its secrets to 
investigators wielding the standard genetics tools including knockout mice, RNA 
interference, and dominant-negative allele expression. Furthermore, we have 
expressed a fragment of TRF2 containing just the hRAP1 interaction domain (a.a. 
280-446). This fragment should bind and occupy the TRF2 binding site on hRAP1, 
disrupting the association of endogenous hRAP1 and TRF2 thereby preventing 
hRAP1 from localizing to telomeres. Although we saw a dramatic reduction in 
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hRAP1 at telomeres in this experiment, no telomere deprotection phenotype was 
observed (Figure 5.1a and b). The lack of success of this and other hRAP1 loss-of-
function experiments[66, 69, 144] can be explained by three possibilities, either that 
hRAP1 does not normally contribute to telomere protection, that very little hRAP1 is 
needed to protect telomeres, or that hRAP1 is one among many proteins that have 
redundant roles in telomere protection. 
 
Figure 5.1: Analysis of HeLa S3 cells expressing TRF2277-446. (a) HeLa S3 were 
stained with TRF2 (green) and hRAP1 antibodies (red). DNA was visualized with 
DAPI (blue). (b) Telomere-FISH on metaphase spreads from HeLa S3 expressing 
TRF2277-446 . Telomeres are detected with an LNA probe that detects the G-rich 
telomeric DNA strand (green). DNA visualized with DAPI (red). 
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Since hRAP1 loss of function experiments have proven unwieldy to date, a 
more productive approach may be to further characterize the telomere protection 
afforded by hRAP1 in the in vitro and in vivo NHEJ assays reported in Chapter 
Three. For example, we have started to perform domain mapping to identify the 
minimum domain of hRAP1 that is sufficient to protect telomeres from the loss of 
TRF2/ hRAP1. Results presented in Chapter Three indicate that the TRF2 interaction 
domain on hRAP1 is dispensable for telomere protection and demonstrate that the 
domain mapping strategy can be successfully employed in this system. Concurrent 
deletion of other domains in hRAP1 including the BrCT, Myb, and coiled-coil 
domains may identify key regions of hRAP1 involved in telomere protection. The 
strength of this system is that it can be used both in vitro and in vivo, such that one 
could immunodeplete TRF2 and hRAP1 from NHEJ extract and add purified 
hRAP1-TebDB with the hRAP1-Myb domain deleted. Hypothetically, if this fusion 
protein was unable to restore telomere protection, the Myb domain would be a strong 
candidate for a region in hRAP1 that is responsible for telomere protection. One 
could then take the same hRAP1-TebDB construct with the Myb and TRF2-
interaction domains removed (to prevent recruitment of TRF2ΔBΔM to telomeres) 
and co-express it with TRF2ΔBΔM. If telomere deprotection persisted in this sample, 
this data would support the model that the Myb domain is critical for telomere 
protection, and the convergence of in vitro and in vivo data would strongly justify 
pursuing this project further. 
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Having putatively identified regions of hRAP1 that are important for 
telomere protection, one could then try to discover factors that interact with that 
domain of hRAP1. This could be accomplished by many straightforward strategies, 
including yeast-2-hybrid technology[178] or immunoprecipitation of an epitope-
tagged hRAP1 fragment containing only the domain of interest coupled with mass 
spectrometry to identify other peptides/proteins in the immunoprecipitation eluate 
[179]. Mass spectrometry would have the added advantage of being able to identify 
post-translational modifications in critical hRAP1 domains that may be necessary for 
end protection. It is likely that the hRAP1 associated proteins may work together 
with hRAP1 to ensure telomere protection, and their identification may help solve 
the enigma of hRAP1’s role in telomere maintenance.  
Another set of experiments that could help address hRAP1’s role in telomere 
protection involves the analysis of damage signaling at telomeres containing hRAP1 
but devoid of TRF2. Previous work has demonstrated that telomeres in TRF2 
deficient MEFs signal for DNA damage through the ATM pathway, as deletion of 
ATM in TRF2 null MEFs abrogates the telomere fusion phenotype associated with 
TRF2 deletion [75]. In addition, other reports have suggested that TRF2 can bind and 
directly inhibit the autophosphorylation of ATM, a critical event in damage 
signaling, and that TRF2 can also bind the ATM effector Chk2 [59, 60]. The 
functional significance of these interactions in telomere protection is not yet known, 
however. It is also possible that hRAP1 inhibits damage signaling through unknown 
mechanisms. To address this possibility, quantification of the DNA damage response 
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and DNA repair both at telomeres and in whole cell extracts can be performed. For 
example, immunofluorescence with antibodies against different DNA damage and 
repair proteins, including 53BP1, phospho-H2AX, phospho-ATM, and others may 
show different staining patterns at hRAP1-containing and deficient telomeres [145]. 
Western blotting of whole cell extracts from cells expressing hRAP1-TebDB with 
TRF2ΔBΔM may also reveal differences in both the types and relative amounts of 
damage signaling in cells. These experiments would help pinpoint hRAP1’s site of 
action in the DNA damage and repair signaling cascades. 
 The second question put forth by Chapter Three pertains to the idea that 
multiple pathways inhibit NHEJ at telomeres [68]. The experimental strategy 
outlined in Chapter Three provides an opportunity to capitalize on the TebDB system 
for the study of proteins that localize both to telomeres and other parts of the 
genome. PNUTS and MCPH1 are recently identified TRF2 interacting factors and, 
interestingly, mutation of their binding site in TRF2ΔBΔM reduced the telomere 
deprotection phenotype associated with expression of this allele [143]. It is possible 
that they play redundant roles with hRAP1 in protecting telomeres from NHEJ. To 
dissect any potential contribution of these proteins to telomere protection, one could 
fuse either PNUTS or MCPH1 to TebDB and co-express that fusion protein with 
TRF2ΔBΔM. If telomere protection was observed (and relevant controls such as 
those used in Chapter Three supported this result), the data would suggest that 
protein plays a role in telomere protection. To further investigate the issue, one could 
look for a synergistic effect of loss of function of both hRAP1 and the newly 
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identified telomere protection factor, perhaps by knocking down both mRNAs 
concurrently using RNA interference. The emergence of a telomere fusion phenotype 
when both hRAP1 and the other protein are knocked down, while knockdown of 
either alone is innocuous, would argue for the multiple pathway hypothesis and 
provide the first evidence for multi-modal NHEJ inhibition at telomeres in 
metazoans. It is worth noting that this type of experiment could be conducted by 
fusing any protein of interest to TebDB and assaying its ability to inhibit telomere 
end-joining, which is a timely discovery given recent reports suggesting that over 
200 different proteins reside at telomeres [180]. 
 
V.2: Future directions for Chapter 4 
 While Chapter Three of this thesis provides several new avenues of 
investigation for telomere researchers, Chapter Four’s contribution to the expanding 
literature of semi-conservative DNA synthesis at telomeres should not be 
overlooked. In Chapter Four, we show that abrogation of telomere replication by 
TRF2ΔB expression in transformed cell lines leads to dynamic telomere associations 
that are reminiscent of the telomere entanglements associated with replication stress 
in fission yeast [129]. Furthermore, we demonstrate that these human telomere 
entanglements are telomerase and NHEJ-independent and contain telomeric DNA 
and telomere binding proteins. Finally, we show that WRN deficient cell lines are 
resistant to this type of dysfunction, further linking these telomere associations to 
telomere replication stress and fission yeast telomere entanglements. 
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 Chapter Four reports two important results that can be used to pursue 
research in the area of telomere replication. First, the identification of chromatin 
bridges between sister nuclei in interphase that contain large amounts of telomeric 
DNA provides a readily detectable phenotype for screening, particularly by 
automated microscopy platforms. For example, one could seed cells in a 96-well 
glass bottom dish, treat the cells with a siRNA library, and perform high-throughput 
telomere-FISH[181] on the cultured cells 72hr after transfection to look for 
chromatin bridges that are positive for telomeric DNA. Visualization of such 
structures would identify siRNAs that induce telomere replication stress. This 
experiment would uncover other factors associated with telomere replication, and 
may provide insight into how the cell deals with difficult-to-replicate regions. 
Another experiment that uses the same strategy would be to seed cells in a 96 well 
dish, transfect the cells with a siRNA library, and then transfect the cells with 
TRF2ΔB. If cells that are resistant to telomere entanglement formation are observed, 
then it is likely that the siRNA target gene in that well plays a role in the 
development of replication stress at telomeres, and may also shed light on the 
etiology of replication stress-associated at telomeres.  
 Although we have identified a new type of telomere-associated replication 
stress, the incidence and prevalence of these events in human cells is not known. To 
better understand telomere entanglements’ etiology and contribution to pathology, 
multiple complementary strategies must be employed. For instance, information 
about the etiology of telomere entanglements may be gained by dissecting the 
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signaling cascade that arises when such insults are experienced by the cell. Fission 
yeast telomere entanglements were shown to activate mitotic spindle checkpoints, 
thereby providing an explanation for their ability to halt cell cycle progression [129]. 
In order to dissect damage signaling associated with human telomere entanglements, 
a reasonable approach is to compare relative levels of activated DNA damage 
response proteins using Western Blotting. DNA damage response kinases of interest 
in this regard include ATM phosphorylated on serine 1981 and ATR phosphorylated 
on serine 428, as well as their downstream substrates Chk1 phosphorylated on serine 
296 and Chk2 phosphorylated on threonine 68. Phosphospecific antibodies for these 
proteins are available, allowing for molecular dissection of the signaling pathway 
involved in mammalian telomere entanglement formation. Replication stress at other 
loci such as fragile sites primarily involves signaling by ATR [182], therefore 
analysis of telomere entanglements may show that they are similar to other 
dysfunctions whose etiology is better understood. Illuminating differences between 
entanglements and other types of telomere dysfunction, including NHEJ-dependent 
fusions that signal through ATM, may also help to shed light on their origins. 
Because fragile site-associated replication stress leads to genomic 
rearrangements often observed in cancers [183], it is also important to understand 
how telomere-associated replication stress may be involved in carcinogenesis. For 
example, if replication stress occurs at telomeres, the inability to repair such an insult 
is likely to result in cellular senescence-a normally irreversible cell cycle arrest that 
can be bypassed by oncogenic changes including p53 and Rb inactivation or Ras 
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activation [184, 185]. The bypass of senescence induced by telomere-associated 
replication stress is expected to result in telomere entanglements like those reported 
in Chapter Four. Since this phenotype very obviously results in telomere-mediated 
genome instability and telomere instability can contribute to oncogenesis [186], it is 
reasonable to hypothesize that the genome instability reported in Chapter Four may 
actually drive tumorigenesis.  Thus, a new link between telomere dysfunction and 
oncogenesis may be uncovered, namely that telomere replication stress can result in 
genome instability that leads to oncogenic transformation. However, no such 
evidence for this model exists to date, though it has been shown that the highly 
oncogenic RasV12 causes cellular senescence by promoting DNA hyperreplication 
with concomitant induction of the DNA damage response [187]. The contribution of 
telomere replication to Ras-induced senescence was not addressed, though. 
 Dissecting the contribution of telomere replication to carcinogenesis poses a 
daunting challenge. However, tractable entry points do exist. Intriguing similarities 
between ALT cells and cells experiencing telomere-specific replication stress have 
been reported here and elsewhere and include homologous recombination proteins 
acting at telomeres, spontaneous t-circle formation, dramatic telomere length 
heterogeneity, telomere-free chromosome ends, and unresolved telomeric HR 
intermediates [54, 174, 180, 188]. Currently, it is not known how cancer cells engage 
the ALT pathway on their route to immortality. Thus, the identification of reagents 
that can promote engagement of ALT may shed light on its etiology. The similarities 
between ALT and replication stress at telomeres implies a causal relationship, 
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suggesting that telomere-specific replication stress can promote ALT. This idea is 
exciting because telomeres are inherently difficult to replicate, as evidenced by their 
exquisite sensitivity to DNA replication inhibitors[55]. To investigate this novel 
hypothesis, an interesting and reasonable experiment is to “pulse” untransformed 
cells with an inducer of telomere-specific replication stress like TebDB or TRF2ΔB 
during the process of transformation and then calculate the frequency of ALT in 
clones derived after transformation. The prediction that stimulating homologous 
recombination between telomeres may predispose cells to engaging ALT could 
therefore be directly addressed.  
 Chapter Four not only provides a potential link between telomere replication 
and oncogenesis, it also provides a tool for investigation of this relationship in any 
organism with telomeric repeats comprised of the sequence 5’TTAGGG3’. To 
address the contribution of telomere-associated replication stress to tumorigenesis, 
an attractive idea is to induce replication stress specifically at telomeres in a living 
animal and measure the incidence of cancer. Since TebDB induces telomere-specific 
replication stress due to its exquisite affinity and specificity for TTAGGG repeats, 
one could construct a transgenic animal; zebrafish, X. laevis, or mouse that expresses 
TebDB under the control of an inducible promoter, such that specific temporal 
induction of TebDB can be achieved. After constructing a transgenic animal, the 
induction of TebDB expression should lead to inhibition of telomere replication only 
in frequently dividing cells, such as skin, gut, and immune system cells, leaving 
differentiated and non-dividing cells like neurons unharmed. Assaying for an 
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increased incidence of carcinomas, intestinal polyps, and lymphomas would then 
address the contribution of telomere-associated replication stress to cancer 
susceptibility.  
 The use of non-human vertebrates to model human diseases is widespread in 
biology. However, due to the difficulties associated with the “anticipation” observed 
in diseases such as DKC and Werner’s syndrome, few animal models for these 
diseases exist, and those that do often do not fully recapitulate the human condition 
[188-191]. Recently, the identification of DKC-like phenotypes in a mutant mouse 
engineered to undergo telomere degradation has brought renewed interest to this 
field [191]. However, this mouse is difficult to make as it requires knockout of two 
different genes, restricting the number of mice strains in which the disease can be 
modeled. The identification of two proteins, Trf2ΔB and TebDB, that can potently 
induce telomere degradation provides new reagents to make multiple mice strains in 
which either of these proteins are inducibly expressed. It is likely that expression of 
these proteins will induce telomere dysfunction and may give investigators the 
opportunity to study DKC and Werner’s Syndrome on demand instead of having to 
wait many generations for diseased mice. Since transgenic mice are much easier and 
cheaper to make than gene targeted knockouts, this experiment should be given 
serious consideration. An even cheaper alternative is to produce a zebrafish that 
inducibly expresses these proteins. The recent identification of zebrafish mutants 
with premature aging phenotypes related to abrogation of telomerase function 
suggests that diseases such as DKC and Werner’s Syndrome can be modeled in these 
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organisms [192]. Fish strains that inducibly express TRF2ΔB or TebDB may be able 
to quickly recapitulate these diseases on demand, which may open new avenues for 
investigation of therapeutic interventions. 
 Another attractive use of TebDB is in the investigation of the contribution of 
individual cells (and their ability to propagate) to tissue maintenance. An example of 
this comes from the zebrafish retina. After encountering massive photoreceptor cell 
death due to overexposure to light, Muller glia within the injured retina 
dedifferentiate into multipotent progenitor cells [193, 194]. Since injured zebrafish 
retinas can regenerate photoreceptors after injury, it has been hypothesized that 
dedifferentiated Muller glia may redifferentiate into photoreceptors to replenish the 
depleted supply. However, it is also possible that other retinal stem cell populations 
are responsible for most of the photoreceptor replacement [195]. Surprisingly, 
TebDB may provide a useful  tool to address this question. As Muller cell-specific 
promoters are available [196], one could drive expression of TebDB in Muller glia of 
adult zebrafish and then injure the retina. Since TebDB would hinder the ability of 
Muller glia to divide by interfering with telomere replication, while leaving the rest 
of the functions of Muller glia intact, one could tease apart the contributions of 
proliferation and cell function to retinal repair. Thus, TebDB provides a new tool that 
can help to dissect the contributions of cell function and proliferation to tissue health 
that contrasts with standard methods such as cell ablation, in which both proliferative 
capacity and function of individual cells are lost upon cell death. 
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 The development of a transgenic animal to investigate the association 
between replication stress at telomeres, genome instability and tumorigenesis is both 
expensive and risky. However, other more conventional uses of TebDB exist. 
Perhaps the most important of these is the use of TebDB as a tool to visualize 
telomeres in vertebrates for which other genomics tools are not available, including 
many species that are relevant to human health and disease [197]. For example, new 
vertebrate model systems including marmosets, naked mole rats, opossums, bats, 
finches, chameleons, and icefish are currently being developed to study important 
biological processes such as aging. Since telomere dynamics may contribute to 
aging-related processes [198], the creation of tools to rapidly visualize telomeres is 
of high interest. Although TRF1/2 homologues in many of these organisms have not 
been identified rendering fusion of fluorescent proteins to endogenous telomere 
binding proteins impossible, GFP-TebDB could be used to visualize telomeres in 
these species. The small size of TebDB suggests that it can be used in virus-based 
gene delivery systems with broad tropisms, allowing for efficient delivery in a wide 
variety of genetically intractable species. It is hoped that these experiments will 
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